



(86) Date de dépôt PCT/PCT Filing Date: 2005/08/09
(87) Date publication PCT/PCT Publication Date: 2006/02/23
(85) Entrée phase nationale/National Entry: 2007/02/01
(86) N° demande PCT/PCT Application No.: EP 2005/008626
(87) N° publication PCT/PCT Publication No.: 2006/018185
(30) Priorité/Priority: 2004/08/14 (EP04019359.1)

(51) Cl.Int./Int.Cl. *A61K 31/525* (2006.01),
A61K 31/5377 (2006.01), *A61P 1/00* (2006.01),
A61P 17/06 (2006.01), *A61P 19/02* (2006.01),
A61P 3/10 (2006.01), *A61P 31/10* (2006.01),
A61P 35/00 (2006.01), *A61P 35/02* (2006.01),
A61P 35/04 (2006.01), *A61P 37/00* (2006.01)


(71) Demandeur/Applicant:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH,
DE

(72) Inventeurs/Inventors:
MUNZERT, GERD, DE;
STEEGMAIER, MARTIN, DE

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : DIHYDROPTERIDINONES POUR LE TRAITEMENT DE MALADIES CANCEREUSES

(54) Title: DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES



(57) **Abrégé/Abstract:**

The present invention relates to the use of a compound of general Formula (1), for the treatment of diseases characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators like cancer selected from the group consisting of carcinomas, sarcomas, melanomas, myeloma, hematologic neoplasias, lymphomas, childhood cancers and leukemia, autoimmune disorders selected from the group consisting of amyloidosis, systemic lupus erythematosus, rheumatoid arthritis, Crohn's disease, multiple sclerosis, systemic sclerosis (scleroderma), mixed connective tissue disease, Sjögren's syndrome, ankylosing spondylitis, autoimmune vasculitis, Behcet's syndrome, psoriasis, autoimmune arthritis, sarcoidosis, diabetes mellitus and fungous diseases.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

PCT

(43) International Publication Date
23 February 2006 (23.02.2006)(10) International Publication Number
WO 2006/018185 A3

(51) International Patent Classification:

A61K 31/525 (2006.01) **A61P 35/00** (2006.01)
A61P 3/10 (2006.01) **A61P 35/02** (2006.01)
A61P 17/06 (2006.01) **A61P 35/04** (2006.01)
A61P 19/02 (2006.01) **A61P 31/10** (2006.01)
A61P 1/00 (2006.01) **A61K 31/5377** (2006.01)
A61P 37/00 (2006.01)

(21) International Application Number:

PCT/EP2005/008626

(22) International Filing Date: 9 August 2005 (09.08.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

04019359.1 14 August 2004 (14.08.2004) EP

(71) Applicant (for all designated States except DE, US):
BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Binger Strasse 173, 55216 Ingelheim (DE).(71) Applicant (for DE only): **BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG** [DE/DE]; Binger Strasse 173, 55216 Ingelheim (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MUNZERT, Gerd** [DE/DE]; Merianweg 64, 89075 Ulm (DE). **STEEG-MAIER, Martin** [DE/AT]; Pasteurgasse 4/13, A-1090 Wien (AT).(74) Common Representative: **BOEHRINGER INGELHEIM INTERNATIONAL GMBH**; Binger Strasse 173, 55216 Ingelheim (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report


(88) Date of publication of the international search report:
13 April 2006(48) Date of publication of this corrected version:
1 June 2006

(15) Information about Correction:

see PCT Gazette No. 22/2006 of 1 June 2006

[Continued on next page]

(54) Title: DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES



(57) Abstract: The present invention relates to the use of a compound of general Formula (1), for the treatment of diseases characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators like cancer selected from the group consisting of carcinomas, sarcomas, melanomas, myeloma, hematologic neoplasias, lymphomas, childhood cancers and leukemia, autoimmune disorders selected from the group consisting of amyloidosis, systemic lupus erythematosus, rheumatoid arthritis, Crohn's disease, multiple sclerosis, systemic sclerosis (scleroderma), mixed connective tissue disease, Sjögren's syndrome, ankylosing spondylitis, autoimmune vasculitis, Behcet's syndrome, psoriasis, autoimmune arthritis, sarcoidosis, diabetes mellitus and fungous diseases.

WO 2006/018185 A3


WO 2006/018185 A3



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Dihydropteridinones for the treatment of cancer diseases

The present invention relates to dihydropteridinones of general Formula (I),



wherein the groups L, R¹, R², R³, R⁴ and R⁵ have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and their use in cancer therapy.

Background of the invention

Polo-like kinases (PLKs) are serine/ threonine kinases that play important roles in regulating processes in the cell cycle. There are four PLKs disclosed in the state of the art, i.e. PLK-1, PLK-2, PLK-3 and PLK-4. PLKs play a role in the regulation of the eukaryotic cell cycle (e.g. regulation of the mitotic machinery in mammalian cells). Especially for PLK-1 a central role with respect to the regulation of mitosis is shown (Glover et al. 1998, *Genes Dev.* **12**:3777-87; Qian et al. 2001, *Mol Biol Cell.* **12**:1791-9). Overexpression of PLK-1 seems to be strongly associated with neoplastic cells including cancers (WO 2004/014899). Overexpression of PLK1 has been documented

for various tumor types such as non-small cell lung cancer, squamous cell carcinomas, breast, ovary or papillary carcinomas as well as colorectal cancers (Wolf et al. 1997, *Oncogene* **14**, pages 543-549; Knecht et al. 1999, *Cancer Res.* **59**, pages 2794-2797; Wolf et al. 2000, *Pathol Res Pract.* **196**, pages 753-759; Weichert et al. 2004, *Br. J. Cancer* **90**, pages 815-821; Ito et al. 2004, *Br. J. Cancer* **90**, pages 414-418; Takahashi et al. 2003, *Cancer Sci.* **94**, pages 148-152).


It is the purpose of the present invention to provide compounds for the treatment of various cancer diseases.

10

Detailed description of the invention

The invention relates to the use of compounds of Formula (I),

15



wherein

20 R^1 , R^2 which may be identical or different, denote hydrogen or optionally substituted C_1 - C_6 -alkyl,
or
 R^1 and R^2 together denote a 2- to 5-membered alkyl bridge which may contain 1 to 2 heteroatoms,

R^3 denotes hydrogen or a group selected from among optionally substituted C_1 - C_{12} -alkyl, C_2 - C_{12} -alkenyl, C_2 - C_{12} -alkynyl and C_6 - C_{14} -aryl, or

a group selected from among optionally substituted and/or bridged C_3 - C_{12} -cycloalkyl,
 5 C_3 - C_{12} -cycloalkenyl, C_7 - C_{12} -polycycloalkyl, C_7 - C_{12} -polycycloalkenyl, C_5 - C_{12} -spirocycloalkyl, C_3 - C_{12} -heterocycloalkyl which contains 1 to 2 heteroatoms, and C_3 - C_{12} -heterocycloalkenyl which contains 1 to 2 heteroatoms, or

R^1 and R^3 or R^2 and R^3 together denote a saturated or unsaturated C_3 - C_4 -alkyl bridge
 10 which may contain 1 heteroatom,

R^4 denotes a group selected from among hydrogen, -CN, hydroxy, - NR_6R_7 and halogen, or

a group selected from among optionally substituted C_1 - C_6 -alkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl,
 15 alkynyl, C_1 - C_5 -alkyloxy, C_2 - C_5 -alkenyloxy, C_2 - C_5 -alkynyloxy, C_1 - C_6 -alkylthio, C_1 - C_6 -alkylsulphoxo and C_1 - C_6 -alkylsulphonyl,

L denotes a linker selected from among optionally substituted C_2 - C_{10} -alkyl, C_2 - C_{10} -alkenyl, C_6 - C_{14} -aryl, - C_2 - C_4 -alkyl- C_6 - C_{14} -aryl, - C_6 - C_{14} -aryl- C_1 - C_4 -alkyl, optionally
 20 bridged C_3 - C_{12} -cycloalkyl and heteroaryl which contains 1 or 2 nitrogen atoms,

n denotes 0 or 1

m denotes 1 or 2

25 R^5 denotes a group selected from among optionally substituted morpholinyl, piperidinyl, piperazinyl, piperazinylcarbonyl, pyrrolidinyl, tropenyl, R^8 -diketomethylpiperazinyl, sulphoxomorpholinyl, sulphonylmorpholinyl, thiomorpholinyl, - NR^8R^9 and azacycloheptyl,

R^6 , R^7 which may be identical or different, denote hydrogen or C_1 - C_4 -alkyl,
 30 and

R^8 , R^9 denote unsubstituted nitrogen substituents at R^5 , which may be identical or different, denote either hydrogen or a group selected from among C_1 - C_6 -alkyl, - C_1 - C_4 -alkyl- C_3 - C_{10} -cycloalkyl, C_3 - C_{10} -cycloalkyl, C_6 - C_{14} -aryl, - C_1 - C_4 -alkyl- C_6 - C_{14} -aryl,

pyranyl, pyridinyl, pyrimidinyl, C₁-C₄-alkyloxycarbonyl, C₆-C₁₄-arylcarbonyl, C₁-C₄-alkylcarbonyl, C₆-C₁₄-arylmethyloxycarbonyl, C₆-C₁₄-arylsulphonyl, C₁-C₄-alkylsulphonyl and C₆-C₁₄-aryl-C₁-C₄-alkylsulphonyl,

- 5 optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof,
- 10 for the preparation of a pharmaceutical composition for the treatment of diseases characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators.

- Preferred is the use according to the invention of compounds of Formula (I) wherein
- 15 R¹ to R⁴, R⁶ and R⁷ are as hereinbefore defined, and
- L denotes a linker selected from among optionally substituted C₂-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₆-C₁₄-aryl, -C₂-C₄-alkyl-C₆-C₁₄-aryl, -C₆-C₁₄-aryl-C₁-C₄-alkyl, optionally bridged C₃-C₁₂-cycloalkyl and heteroaryl which contains 1 or 2 nitrogen atoms
- n denotes 1
- 20 m denotes 1 or 2
- R⁵ denotes a group which is bound to L via a nitrogen atom, selected from among optionally substituted morpholinyl, piperidinyl, R⁸-piperazinyl, pyrrolidinyl, tropenyl, R⁸-diketomethylpiperazinyl, sulphoxomorpholinyl, sulphonylmorpholinyl, thiomorpholinyl, -NR⁸R⁹ and azacycloheptyl,
- 25 R⁸, R⁹ denote unsubstituted nitrogen substituents at R⁵, which may be identical or different, hydrogen or a group selected from among C₁-C₆-alkyl, -C₁-C₄-alkyl-C₃-C₁₀-cycloalkyl, C₃-C₁₀-cycloalkyl, C₆-C₁₄-aryl, -C₁-C₄-alkyl-C₆-C₁₄-aryl, pyranyl, pyridinyl, pyrimidinyl, C₁-C₄-alkyloxycarbonyl, C₆-C₁₄-arylcarbonyl, C₁-C₄-alkylcarbonyl, C₆-C₁₄-arylmethyloxycarbonyl, C₆-C₁₄-arylsulphonyl, C₁-C₄-alkylsulphonyl and C₆-C₁₄-aryl-C₁-C₄-alkylsulphonyl,
- 30

optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof.

5 Also preferred is the use according to the invention of compounds of Formula (I), wherein

R^1 to R^4 , R^6 and R^7 are as hereinbefore defined,

L denotes a linker selected from among optionally substituted C_2 - C_{10} -alkyl, C_2 - C_{10} -alkenyl, C_6 - C_{14} -aryl, $-C_2$ - C_4 -alkyl- C_6 - C_{14} -aryl, $-C_6$ - C_{14} -aryl- C_1 - C_4 -alkyl, optionally
10 bridged C_3 - C_{12} -cycloalkyl and heteroaryl which contains 1 or 2 nitrogen atoms

n denotes 0 or 1

m denotes 1 or 2

R^5 denotes a group which is bound to L via a carbon atom, selected from among R^8 - piperidinyl, R^8R^9 -piperazinyl, R^8 -pyrrolidinyl, R^8 - piperazinylcarbonyl, R^8 -tropanyl, R^8 -
15 morpholinyl and R^8 -azacycloheptyl,
and

R^8 , R^9 denote unsubstituted nitrogen substituents at R^5 , which may be identical or different, hydrogen or a group selected from among C_1 - C_6 -alkyl, $-C_1$ - C_4 -alkyl- C_3 - C_{10} -cycloalkyl, C_3 - C_{10} -cycloalkyl, C_6 - C_{14} -aryl, $-C_1$ - C_4 -alkyl- C_6 - C_{14} -aryl, pyranyl, pyridinyl,
20 pyrimidinyl, C_1 - C_4 -alkyloxycarbonyl, C_6 - C_{14} -arylcarbonyl, C_1 - C_4 -alkylcarbonyl, C_6 - C_{14} -arylmethyloxycarbonyl, C_6 - C_{14} -arylsulphonyl, C_1 - C_4 -alkylsulphonyl and C_6 - C_{14} -aryl- C_1 - C_4 -alkylsulphonyl,

optionally in the form of the tautomers, the racemates, the enantiomers, the
25 diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof.

Particularly preferred is the use of compounds of Formula (I) wherein

L, m, n and R^3 to R^9 are as hereinbefore defined, and

30 R^1 , R^2 which may be identical or different, denote a group selected from among hydrogen, Me, Et, Pr, or
 R^1 and R^2 together form a C_2 - C_4 -alkyl bridge,

optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof.

- 5 Especially preferred is the use according to the invention of compounds of Formula (I) wherein

R^1 , R^2 , m , n and R^5 to R^8 are as hereinbefore defined, and

R^3 denotes a group selected from among optionally substituted C_1 - C_{10} -alkyl, C_3 - C_7 -cycloalkyl, C_3 - C_6 -heterocycloalkyl and C_6 - C_{14} -aryl or

- 10 R^1 and R^3 or R^2 and R^3 together denote a saturated or unsaturated C_3 - C_4 -alkyl bridge which may contain 1 to 2 heteroatoms,

R^4 denotes a group selected from among hydrogen, OMe, OH, Me, Et, Pr, OEt, NHMe, NH_2 , F, Cl, Br, O-propargyl, O-butynyl, CN, SMe, NMe₂, CONH₂, ethynyl, propynyl, butynyl and allyl,

- 15 and


L denotes a linker selected from among optionally substituted phenyl, phenylmethyl, cyclohexyl and branched C_1 - C_6 -alkyl,

optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically





















- 20 acceptable acid addition salts thereof.

In a further embodiment, the present invention relates to the use of a compound of Formula (I) according to the invention, wherein the compound is selected from the group consisting of the compounds of Formula (I) shown in the following Table

25



Ex.	R ¹	R ²	Config. R ¹ or R ²	R ³	R ⁴	L _n -R ⁵ _m
27	H		R			
44	H		R		H	
55	H		R			
58	H		R			
102	H		R			
103	H		R			
105	H		R			

110	H		R			
115	H		R			
133	H		R			
134	H		R			
234	H		R			
240	H		R			

wherein the abbreviations X_1 , X_2 , X_3 , X_4 and X_5 used in the Table in each case denote a link to a position in the general Formula shown in the Table instead of the corresponding groups R^1 , R^2 , R^3 , R^4 and $L-R^5$.

5

In a preferred embodiment the invention relates to the use of a compound of Formula (I) according to the invention, wherein the polo-like kinase is PLK-1.

In another preferred embodiment the invention relates to the use of a compound of Formula (I) according to the invention, wherein the disease is characterized by inappropriate cellular proliferation, migration, apoptosis or angiogenesis, preferably by inappropriate cellular proliferation. Inappropriate cell proliferation means cellular proliferation resulting from inappropriate cell growth, from excessive cell division, from cell division at an accelerated rate and/or from inappropriate cell survival.

In another preferred embodiment the invention relates to the use of a compound of Formula (I) according to the invention, wherein the disease is cancer selected from the group consisting of carcinomas, sarcomas, melanomas, myelomas, hematological neoplasias, lymphomas and childhood cancers.

Examples of carcinomas within the scope of the invention include but are not limited to adenocarcinoma (AC), squamous cell carcinoma (SCC) and mixed or undifferentiated carcinomas. Carcinomas within the scope of the invention include but are not limited to the following histologies:

- Head and neck tumours: SCC, AC, transitional cell cancers, mucoepidermoid cancers, undifferentiated carcinomas;
- Central nervous system tumours: Astrocytoma, glioblastoma, meningioma, neurinoma, schwannoma, ependymoma, hypophysoma, oligodendroglioma, medulloblastoma;
- Bronchial and mediastinal tumours:
 - Bronchial tumours:
 - Small cell lung cancers (SCLC): oat-cell lung cancer, intermediate cell cancer, combined oat-cell lung cancer;
 - Non-small cell lung cancers (NSCLC): SCC, spindle cell carcinoma, AC, bronchioalveolar carcinoma, large cell NSCLC, clear cell NSCLC;
 - Mesothelioma;
 - Thymoma;
 - Thyroid carcinomas: papillary, follicular, anaplastic, medullary;
- Tumours of the gastrointestinal tract:
 - Oesophageal cancers: SCC, AC, anaplastic, carcinoid, sarcoma;
 - Gastric cancers: AC, adenosquamous, anaplastic;

- Colorectal cancers: AC, including hereditary forms of AC, carcinoid, sarcoma;
 - Anal cancers: SCC, transitional epithelial cancer, AC, basal cell carcinoma;
 - Pancreatic cancers: AC, including ductal and acinary cancers, papillary, adenosquamous, undifferentiated, tumours of the endocrine pancreas;
 - Hepatocellular carcinoma, cholangiocarcinoma, angiosarcoma, hepatoblastoma;
 - Biliary carcinomas: AC, SCC, small cell, undifferentiated;
 - Gastrointestinal stroma tumours (GIST);
- Gynaecological cancers:
 - Breast cancers: AC, including invasive ductal, lobular and medullary cancers, tubular, mucinous cancers, Paget-carcinoma, inflammatory carcinoma, ductal and lobular carcinoma in situ;
 - Ovarian cancers: Epithelial tumours, stroma tumours, germ cell tumours, undifferentiated tumours;
 - Cervical cancers: SCC, AC, mixed and undifferentiated tumours;
 - Endometrial cancers: AC, SCC, mixed, undifferentiated tumours;
 - Vulvar cancers: SCC, AC;
 - Vaginal cancers: SCC, AC;
- Urinary tract and testicular cancers:
 - Testicular cancers: seminoma;
 - Non-seminomatous germ cell tumours: teratoma, embryonal cell carcinoma, choriocarcinoma, yolk sac tumour, mixed, Sertoli and Leydig-cell tumours;
 - Extragonadal germ cell tumours;
 - Prostate cancers: AC, small cell, SCC;
 - Renal cell cancers: AC, including clear cell, papillary and chromophobous carcinomas, hereditary forms (e.g. von-Hippel-Lindau syndrome), nephroblastoma;
 - Urinary bladder cancers: transitional cell (urothelial) cancers, SCC, AC;
 - Urethral cancers: SCC, transitional cell cancers, AC;
 - Penile cancers: SCC;
- Tumours of endocrine tissue:

- Thyroid cancers: papillary, follicular, anaplastic, medullary carcinomas, including MEN syndrome;
- Tumours of the endocrine pancreas;
- Carcinoids;
- 5 ○ Pheochromocytoma.

Examples of sarcomas within the scope of the invention include but are not limited to Ewing-sarcoma, osteosarcoma or osteogenic sarcoma, chondrosarcoma, synovial sarcoma, leiomyosarcoma, rhabdomyosarcoma, mesothelial sarcoma or mesothelioma, 10 fibrosarcoma, angiosarcoma or hemangioendothelioma, liposarcoma, glioma or astrocytoma, myxosarcoma, malignant fibrous histiocytoma, mesenchymous or mixed mesodermal tumour, neuroblastoma and clear cell sarcoma.

Examples of melanomas within the scope of the invention include but are not limited to 15 superficial spreading melanoma, nodular and lentigo-maligna melanoma.

Examples of myelomas within the scope of the invention include but are not limited to immunocytoma, plasmocytoma and multiple myeloma.

20 In another preferred embodiment the invention relates to the use according to the invention, wherein the hematological neoplasia is leukemia.

Further examples of hematologic neoplasias within the scope of the invention include but are not limited to acute or chronic leukemias of myeloid, erythroid or lymphatic 25 origin, myelodysplastic syndromes (MDS) and myeloproliferative syndromes (MPS, such as chronic myelogeneous leukemia, osteomyelofibrosis, polycythemia vera or essential thrombocythemia).

Examples of lymphomas within the scope of the invention include but are not limited 30 to:

- Hodgkin-lymphoma;
- Non-Hodgkin-lymphomas: T- and B-cell lymphomas
 - B-cell lymphomas:

- Low and intermediate grade: Chronic lymphocytic leukemia (CLL),
prolymphocytic leukemia (PLL), small lymphocytic lymphoma, hairy
cell leukemia, plasmacytoid lymphoma, mantle cell lymphoma, follicular
lymphoma, marginal zone lymphoma including MALT-lymphoma;
- 5 ▪ High grade: diffuse large B-cell lymphoma (DLBCL including
immunoblastic and centroblastic variants), lymphoblastic, Burkitt's
lymphoma;
- T-cell lymphomas:
 - Low grade: T-CLL, T-PLL, Mycosis fungoides, Sezary-syndrome;
 - 10 ▪ High grade: Anaplastic large cell, T-immunoblastic and lymphoblastic.

In another preferred embodiment the invention relates to the use according to the invention, wherein the disease is cancer selected from the group consisting of mixed tumours, undifferentiated tumours and metastases thereof.

15

Examples of mixed tumours within the scope of the invention include but are not limited to adenosquamous carcinomas, mixed mesodermal tumours, carcinosarcomas and teratocarcinomas.

20 Examples of undifferentiated, other tumours or metastases thereof within the scope of the invention include but are not limited to undifferentiated tumours, carcinomas of unknown primary (CUP), metastases of unknown primary (MUP) and pheochromocytoma, carcinoids.

25 In a further embodiment the invention relates to the use of a compound of Formula (I) according to the invention, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical
30 composition for the treatment of autoimmune disorders selected from the group consisting of amyloidosis, systemic lupus erythematosus, rheumatoid arthritis, Crohn's disease, multiple sclerosis, systemic sclerosis (scleroderma), mixed connective tissue

disease, Sjögren's syndrome, ankylosing spondylitis, autoimmune vasculitis, Behcet's syndrome, psoriasis, autoimmune arthritis, sarcoidosis and diabetes mellitus.

In a further embodiment the invention relates to the use of a compound of Formula (I)
5 according to the invention, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of fungous diseases including but not limited to
10 candidiasis, cryptococcosis, aspergillosis, mucormycosis, tinea, dermatophytosis, histoplasmosis, blastomycosis, coccidiosis, pneumocystis.

Homologous genes encoding polo-like kinases have been identified from various eukaryotes ranging from fungi (*S. cerevisiae*, *S. pombe*, *C. albicans*), fly (*D. melanogaster*),
15 worms (*C. elegans*) and vertebrates and represent a central mechanism to regulate mitotic progression (Glover et al. 1996, *J Cell Biol*, 135, pages 1681-1684, Bachewich et al. 2003, *Mol Biol Cell* 14, pages 2163-2180). Thus, the preferentially local or systemic administration of a therapeutically effective amount of a compound of Formula (I), optionally in form of its tautomers, racemates, enantiomers, diastereomers
20 and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs or physiologically functional derivatives thereof, represents a novel approach for treating fungous diseases.

In a further embodiment the invention relates to a method for treating a disease
25 characterized by abnormal cell proliferation in a human or non-human mammalian body comprising administering to the mammal a therapeutically effective amount of a compound of Formula (I), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs or physiologically
30 functional derivatives thereof.

In a further embodiment the invention relates to a method for treating patients who suffer from one or more diseases cited above comprising administering to the patient a

therapeutically effective amount of a compound of Formula (I), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs or physiologically functional derivatives thereof.

5

A method for treating a disease characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators in a mammal comprises regulating, modulating, binding or inhibiting PLK activity and/or overexpression of PLK or one of the other PLK isoforms, preferably PLK-1

10

In a further embodiment the invention relates to the use of a compound of Formula (I) according to the invention, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs or physiologically functional derivatives thereof, wherein the active ingredient is administered orally, enterically, transdermally, intravenously, peritoneally or by injection, preferably intravenously.

15

Within the meaning of the present invention, a compound of Formula (I), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, inhibits the proliferation of various human tumor cell lines including but not limited to Saos-2, H4, MDA-MB-435S, MDA-MB453, MCF7, HeLa S3, HCT116, Colo 205, HT29, FaDu, HL-60, K-562, THP-1, HepG2, A549, NCI-H460, NCI-H520, GRANTA-519, Raji, Ramos, BRO, SKOV-3, BxPC-3, Mia CaPa-2, DU145, PC-3, NCI-N87, MES-SA, SK-UT-1B and A431.

25

The following example illustrates the present invention without restricting its scope.

30

The activity of 4-[[*(7R)*-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-*N*-(1-methyl-4-piperidinyl)-benzamide, which is a compound of Formula (I) according to the invention (Exemplified compound Nr. 46 in

Table 2) can be determined in cytotoxicity tests on cultivated human tumour cells and/or by FACS analysis where its inhibitory effect on cell cycle progression is monitored. In both test methods, this compound exhibits a good to very good activity (see Table 1).

5

Alamar BlueTM cytotoxicity assays

The Alamar BlueTM assay is designed to measure quantitatively the proliferation of cells by incorporating a fluorometric/colorimetric growth indicator based on the detection of metabolic activity.

Cell culture: The various human tumor cell lines can be purchased from American Type Culture Collection (ATCC) or the German Collection of Microorganisms and Cell Cultures (DSMZ) and cultivated in 75 to 175 cm² tissue culture flasks in the medium indicated by the supplier. The cells are maintained at 37°C and 5 % CO₂ in a humidified atmosphere, with an appropriate split ratio. Logarithmically growing cells are used for the assays.

Assay conditions: On day one of the experiment 1000-4000 cells (in 100 µl medium) are seeded into each well of a sterile 96-well plate. The number of cells used is dependent on the growth rate and size of the cells. Eight wells on each plate are left free to accommodate for controls (4 wells for medium plus reduced AlamarBlueTM, and 4 wells for medium plus oxidized AlamarBlueTM). The plates are kept in the incubator overnight. On day two of the experiment serial dilutions of the inhibitor are prepared in medium containing 0.1% DMSO. Typical concentrations used are 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.003 and 0.001 µM. 100 µl of the dilution (2x concentrate) is added to each well to yield a final volume of 200 µl per well. As controls plain medium and medium containing 0.1% DMSO are added to the designated wells. All data points are done in quadruplicates. The cells are then incubated for 72h. After this incubation period 20 µl of AlamarBlueTM is added to each well. As a control, 20 µl of reduced AlamarBlueTM (AlamarBlueTM autoclaved for 30 min) is added to 4 wells without cells, and 20 µl of AlamarBlueTM is added to the remaining 4 wells without cells. After 4-5h of incubation,

the plates are measured in a fluorescence spectrophotometer (excitation 530 nm, emission 590 nm, slits 15, integrate time 0.1).

Data analysis: For calculation the mean value from the quadruplicates is taken and the background is subtracted. The 0.1% DMSO value (the mean obtained from 8 wells with cells in medium with 0.1 % DMSO but no compound) is taken as 100% control. The data is fitted by iterative calculations using a sigmoidal curve analysis program (Graph Pad Prism version 3.03) with variable Hill slope.

10 **FACS analysis on PI stained tumor cells**

Propidium iodine (PI) binds stoichiometrically to double stranded DNA and thus is a suitable agent to measure the DNA content of cells in order to determine the percentage of cells residing in various cell cycle stages (G0/1-, S- and G2/M-phases), whereas cells in G0 or G1 phase do have a diploid DNA content (2N) cells in G2 and M-phase (mitosis) do have a doubled (4N) DNA content.

Cell culture: The various human tumor cell lines can be purchased from American Type Culture Collection (ATCC) or the German Collection of Microorganisms and Cell Cultures (DSMZ) and cultivated in 75 to 175 cm² tissue culture flasks in the medium indicated by the supplier. The cells are maintained at 37°C and 5 % CO₂ in a humidified atmosphere, with an appropriate split ratio. Logarithmically growing cells are used for the assays.

Assay conditions: On day one of the experiment 1×10^6 tumor cells are plated in 15 ml medium onto each 75 cm² tissue culture flask and the cultures are returned to the incubator. On the next day serial twofold dilutions (100x concentrated) of the inhibitor are prepared in tissue culture medium containing 10% DMSO. 150 μ l of the 100x concentrated dilution is added to the 15 ml medium in the flask. As control DMSO is given into a separate flask to yield a final concentration of 0.1%. Typical final concentrations used are 1,6, 08, 0.4, 0.2, 0.1, 0.05, 0.025, 0.0125, 0.00625 μ M in medium containing 0.1% DMSO. After 24 hrs of incubation cells are harvested by 2x wash with PBS and subsequent addition of trypsin/EDTA. Trypsinized cells are washed

off the plastic with 1% BSA in PBS. Non-adherent cells in the medium and cells in the PBS wash fluids are pelleted together with the trypsinized cells by centrifuging them for 5 min at 1000 rpm at 4°C. The supernatants are discarded and the pellet is washed twice with PBS. After aspiration of the supernatants pellets are resuspended in the residual
5 PBS (~100 μ l). For cell fixation, 15 ml test tubes (Falcon) with 5 ml of 80% cold ethanol are prepared and the cell suspension is added slowly and kept for at least 2 h or overnight at minus 20°C. Fixed cells are pelleted, washed once with PBS and the cell pellet is then resuspended in 2 ml of 0.25% Triton X-100 in PBS. After 5 min incubation on ice, 5 ml of PBS is added to each sample and the sample is again
10 centrifuged at 1000 rpm for 5 min at 4°C. The supernatant is discarded and the pellet is resuspended in 0.5 ml propidium iodine (PI) staining solution (0.1% RNase and 10 μ g/ml propidium iodine in PBS). The cells are incubated for 20 min in the dark and subsequently transferred to 5 ml polystyrene round-bottom tubes.

15 **Data analysis:** Analysis of the DNA content of the cells can be performed using a FACS analyzer equipped with an argon laser (500 mW, emission 488 nm) and the use of the DNA Cell Quest analysis software (Beckton Dickinson). The logarithmic PI fluorescence is determined in a band-pass filter (Beckton Dickinson 585/43). Quantification of the cell populations residing in the individual cell cycle phases (e.g.
20 G0/G1-, S- and G2/M-phases) is done with the ModFit LT software package from Becton Dickinson. An EC₅₀ value for cells arrested at the G2/M-phase of the cell cycle is calculated by using a sigmoidal curve analysis program (Graph Pad Prism version 3.03).

Table 1

In vitro efficiency data of 4-[[[(7*R*)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridiny]amino]-3-methoxy-*N*-(1-methyl-4-piperidiny)-benzamide

Tissue origin	Cell lines	Alamar Blue	FACS Analysis
		Cytotoxicity Assay	G2M-Arrest
		EC50 [μ M]	EC50 [μ M]
Bone	Saos-2	0.008	0.011
Brain	H4	0.022	0.039
Breast	MDA-MB-435S	0.017	0.038
	MCF7	0.009	
Cervix	HeLa S3	0.012	0.016
Colon	HCT116	0.009	0.009
	Colo 205	0.009	
	HT29	0.004	
Head and Neck	FaDu	0.006	0.007
Leukemia	HL-60	0.014	
	THP-1	0.009	
Liver	HepG2	0.010	0.039
Lung	A549	0.006	0.014
	NCI-H460	0.014	0.032
	NCI-H520	0.010	0.018
Lymphoma	GRANTA-519	0.005	0.012
	Raji	0.014	0.020
Melanoma	BRO	0.004	
Ovary	SKOV-3	0.004	0.011
Pancreas	BxPC-3	0.025	0.022
	Mia CaPa-2	0.007	

Prostate	DU145	0.006	
	PC-3	0.007	0.012
Stomach	NCI-N87	0.014	
Uterus	MES-SA	0.010	
	SK-UT-1B	0.008	
Vulva	A431	0.002	0.006

A compound of Formula (I), its tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, may be used on their own or combined with other active substances according to the invention, optionally also in conjunction with other pharmacologically active substances.

Suitable pharmaceutical preparations for the use in accordance with the invention include, for example, tablets, capsules, suppositories, solutions, and particularly solutions for injection (s.c., i.v., i.m.) and infusion, syrups, emulsions or dispersible powders. The amount of pharmaceutically active compound in each case should be in the range from 0.1 - 90 wt.%, preferably 0.5 - 50 wt.% of the total composition, i.e. in amounts which are sufficient to achieve the dosage range given below. The doses specified may, if necessary, be given several times a day.

Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.

Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or

prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number of layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.

- 5 Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharin, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of
10 fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.

Solutions for injection and infusion are prepared in the usual way, e.g. with the addition of preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, optionally using emulsifiers and/or dispersants, while
15 if water is used as the diluent organic solvents may optionally be used as solubilisers or auxiliary solvents, and transferred into injection vials or ampoules or infusion bottles.

Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as
20 lactose or sorbitol and packing them into gelatine capsules.

Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.

- 25 Suitable excipients may be, for example, water, pharmaceutically acceptable organic solvents, such as paraffins (e.g. petroleum fractions), oils of vegetable origin (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolin, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silica and silicates), sugar (e.g. glucose, lactose
30 and dextrose), emulsifiers (e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulphate).

The preparations are administered in the usual way, preferably by oral or transdermal route, particularly preferably by oral route. When administered orally the tablets may, of course, contain additives, such as e.g. sodium citrate, calcium carbonate and dicalcium phosphate together with various additives, such as starch, preferably potato starch, gelatine and the like, in addition to the abovementioned carriers. Lubricants such as magnesium stearate, sodium laurylsulphate and talc may also be used to form tablets. In the case of aqueous suspensions the active substances may be combined with various flavour enhancers or colourings in addition to the abovementioned excipients. For parenteral use, solutions of the active substances may be prepared using suitable liquid carrier materials.

The dosage for intravenous use is 1 - 2000 mg per hour, preferably between 5 - 1000 mg per hour.

However, it may optionally be necessary to deviate from the amounts specified, depending on the body weight or method of administration, the individual response to the medication, the nature of the formulation used and the time or interval over which it is administered. Thus, in some cases, it may be sufficient to use less than the minimum quantity specified above, while in other cases the upper limit specified will have to be exceeded. When large amounts are administered it may be advisable to spread them over the day in a number of single doses.

The formulation examples that follow illustrate the present invention without restricting its scope:

25

Examples of pharmaceutical formulations

A)	<u>Tablets</u>	<u>per tablet</u>
30	active substance	100 mg
	lactose	140 mg
	corn starch	240 mg
	polyvinylpyrrolidone	15 mg

magnesium stearate	5 mg
--------------------	------

500 mg

5 The finely ground active substance, lactose and some of the corn starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining corn starch and the magnesium stearate are screened and mixed together. The mixture is compressed to produce tablets of suitable shape and size.

10

B)	<u>Tablets</u>	<u>per tablet</u>
----	----------------	-------------------

active substance	80 mg
------------------	-------

lactose	55 mg
---------	-------

15

corn starch	190 mg
-------------	--------

microcrystalline cellulose	35 mg
----------------------------	-------

polyvinylpyrrolidone	15 mg
----------------------	-------

sodium-carboxymethyl starch	23 mg
-----------------------------	-------

magnesium stearate	2 mg
--------------------	------

20

400 mg

The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and

25 worked with the remaining corn starch and water to form a granulate which is dried and screened. The sodiumcarboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.

30

C) Ampoule solution

active substance	50 mg
------------------	-------

sodium chloride	50 mg
-----------------	-------

water for injection	5 ml
---------------------	------

The active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic. The solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules
 5 which are then sterilised and sealed by fusion. The ampoules contain 5 mg, 25 mg and 50 mg of active substance.

D) Further injectable solutions

Example 1

Active substance	2 mg/ml
Hydrochloric acid 1N	6.8 μ l
NaCl	0.009 g/ml
WFI (water for injection) ad	1 ml
pH	4.5
mOsmol / kg	295

Example 2

Active substance	10.0000 g
Hydrochloric acid 1N	36.6735 g
NaCl	45.0000 g
WFI	4934.8265 g
pH	4.3
mOsmol / kg	300

10

Example 3

Active substance	500 mg
Hydrochloric acid 1N	1.6 ml
NaCl	450.0 mg
WFI ad	50 ml
pH	4.0
mOsmol / kg	290

Example 4

Active substance	0.5 mg
Hydrochloric acid 1N	1.705 μ l
NaCl	9 mg
WFI ad	1 ml
pH	4.8
mOsmol / kg	285

Example 5

Active substance	1 mg
------------------	------

Example 6

Active substance	2 mg
------------------	------

Hydrochloric acid 1N	3.6125 μ l
NaCl	0.009 g
WFI ad	1 ml
pH	4.8
mOsmol / kg	295

Phosphoric acid (85%)	0.440 μ l
NaCl	9 mg
WFI ad	1ml
pH	4.0
mOsmol / kg	298

Example 7

Active substance	100 mg
Acetic acid	16.4 μ l
Dextrose	2.5 g
WFI ad	50 ml
pH	4.4
mOsmol / kg	305

Example 8


Active substance	10 mg
Tartaric acid	4.32 mg
Mannit	0.25 g
WFI ad	5 ml
pH	4.0
mOsmol / kg	298

A process for the manufacture of the compound 4-[[*(7R)*-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridiny]amino]-3-methoxy-*N*-(1-methyl-4-piperidiny)-benzamide is described in WO 03/20722 as well as in WO 04/76454, which are incorporated herein by reference.

However, for the sake of completeness, a process for the manufacture of the compound 4-[[*(7R)*-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridiny]amino]-3-methoxy-*N*-(1-methyl-4-piperidiny)-benzamide is described as well hereinafter. This method is to be understood as an illustration of the invention without restricting it to the subject matter thereof.

Synthesis of 4-[[*(7R)*-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridiny]amino]-3-methoxy-*N*-(1-methyl-4-piperidiny)-benzamide

For the synthesis, first of all an intermediate compound Z3 is prepared as described below.



- 5 54.0 g (0.52 mol) D-2-aminobutyric acid are suspended in 540 mL methanol and slowly combined with 132 g (1.1 mol) thionyl chloride while cooling with ice. The mixture is refluxed for 1.5 h and then evaporated down. The oil remaining is combined with 540 mL tert-butylmethylether and the colourless crystals formed are suction filtered.
Yield: 78.8 g of a compound Z3a (colourless crystals)

10

- 74.2 g of the compound Z3a and 43.5 mL (0.49 mol) cyclopentanone are dissolved in 800 mL dichloromethane. After the addition of 40.0 g (0.49 mol) sodium acetate and 150.0 g (0.71 mol) sodium triacetoxyborohydride at 0°C the mixture is stirred for 12 h at ambient temperature and then 500 mL of 20% sodium hydrogen carbonate solution
15 are added. The aqueous phase is extracted with dichloromethane. The combined organic phases are washed with water, dried over MgSO₄ and evaporated down.
Yield: 85.8 g of a compound Z3b (light yellow oil)

- 40.0 g of the compound Z3b and 30.0 g (0.22 mol) potassium carbonate are suspended
20 in 600 mL acetone and combined with 45.0 g (0.23 mol) 2,4-dichloro-5-nitropyrimidin in 200 mL acetone while cooling with ice. After 12 h a further 5.0 g 2,4-dichloro-5-nitropyrimidin are added and stirred for 3 h. The reaction mixture is evaporated down, taken up in 800 mL ethyl acetate and 600 mL water and the aqueous phase is extracted

with ethyl acetate. The combined organic phases are washed with water, dried over MgSO_4 and evaporated down.

Yield: 75.0 g of a compound Z3c (brown oil)

- 5 100 g of the compound Z3c are dissolved in 650 mL glacial acetic acid and at 70°C 20 g of iron powder are added batchwise. The mixture is stirred for 1 h at 70°C, then for 1.5 h at 100°C and then filtered hot through diatomite (kieselguhr). The reaction mixture is evaporated down, taken up in methanol/dichloromethane, applied to silica gel and purified with ethyl acetate by Soxhlet extraction. The solvent is removed and the
10 residue stirred with methanol.

Yield: 30.0 g of a compound Z3d (light brown crystals)

- 25.0 g of the compound Z3d and 6.5 mL (0.1 mol) methyl iodide are placed in 250 mL dimethylacetamide and at -10°C 3.8 g (0.95 mol) sodium hydride as a 60% dispersion
15 in mineral oil is added. It is stirred for 20 min at 0°C, then for 30 min at ambient temperature and finally ice is added. The reaction mixture is evaporated down and combined with 300 mL water. The precipitate formed is suction filtered and washed with petroleum ether.

Yield: 23.0 g of a compound Z3e (colourless solid)

20

6.0 g of the compound Z3e and 5.1 g (31 mmol) 4-amino-3-methoxybenzoic acid are suspended in 90 mL ethanol and 350 mL water, combined with 3.5 mL concentrated hydrochloric acid and refluxed for 48 h. The reaction mixture is evaporated down, the residue stirred with methanol/diethyl ether and the precipitate formed is suction filtered.

- 25 Yield: 6.3 g of a compound Z3 (light beige crystals)

4-[[*(7R)*-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-*N*-(1-methyl-4-piperidinyl)-benzamide is obtained as described below.

- 30 0.15 g of the compound Z3, 0.12 g TBTU, 0.12 mL DIPEA are dissolved in 5 mL dichloromethane and stirred for 30 minutes at 25°C. Then 50 mg 1-methyl-4-aminopiperidin are added and the mixture is stirred for a further 2.5 hours at 25°C. The

solution is then extracted with water and then evaporated down. The residue is dissolved in warm ethyl acetate and crystallised from ether and petroleum ether. Yield: 0.025 g of white crystals. M.p.: 203°C as the base.


- 5 All compounds of Formula (I) according to the invention may be prepared by the synthesis methods A described hereinafter, while the substituents of general Formula (A1) to (A9) have the meanings given hereinbefore. This method is to be understood as an illustration of the invention without restricting it to the subject matter thereof.

10 Method A

Step 1A

- A compound of Formula (A1) is reacted with a compound of Formula (A2) to obtain a compound of Formula (A3) (Diagram 1A). This reaction may be carried out according to WO 00/43369 or WO 00/43372. Compound (A1) is commercially obtainable, for example, from City Chemical LLC, 139 Allings Crossing Road, West Haven, CT, 06516, USA. Compound (A2) may be prepared by procedures known from the literature: (a) F. Effenberger, U. Burkhardt, J. Willfahrt *Liebigs Ann. Chem.* **1986**, 314-333; (b) T. Fukuyama, C.-K. Jow, M. Cheung, *Tetrahedron Lett.* **1995**, 36, 6373-6374; (c) R. K. Olsen, *J. Org. Chem.* **1970**, 35, 1912-1915; (d) F.E. Dutton, B.H. Byung *Tetrahedron Lett.* **1998**, 30, 5313-5316; (e) J. M. Ranajuhi, M. M. Joullie *Synth. Commun.* **1996**, 26, 1379-1384.).

25 Diagram 1A




In Step 1A, 1 equivalent of the compound (A1) and 1 to 1.5 equivalents, preferably 1.1 equivalents of a base, preferably potassium carbonate, potassium hydrogen carbonate, sodium carbonate or sodium hydrogen carbonate, calcium carbonate, most preferably potassium carbonate, are stirred in a diluent optionally mixed with water, for example
 5 acetone, tetrahydrofuran, diethylether, cyclohexane, petroleum ether or dioxane, preferably cyclohexane or diethylether.

At a temperature of 0 to 15 °C, preferably 5 to 10 °C, 1 equivalent of an amino acid of Formula (A2), dissolved in an organic solvent, for example acetone, tetrahydrofurane,
 10 diethylether, cyclohexane or dioxane, is added dropwise. The reaction mixture is heated to a temperature of 18°C to 30 °C, preferably about 22°C, with stirring and then stirred for a further 10 to 24 hours, preferably about 12 hours. Then the diluent is distilled off, the residue is combined with water and the mixture is extracted two to three times with an organic solvent, such as diethylether or ethyl acetate, preferably ethyl acetate. The
 15 combined organic extracts are dried and the solvent is distilled off. The residue (compound A3) may be used in Step 2 without any prior purification.

Step 2A

20 The compound obtained in Step 1A (A3) is reduced at the nitro group and cyclised to form the compound of Formula (A4) (Diagram 2A).

Diagram 2A



25


In Step 2A , 1 equivalent of the nitro compound (A3) is dissolved in an acid, preferably glacial acetic acid, formic acid or hydrochloric acid, preferably glacial acetic acid, and

heated to 50 to 70°C, preferably about 60°C. Then a reducing agent, for example zinc, tin or iron, preferably iron filings, is added to complete the exothermic reaction and the mixture is stirred for 0.2 to 2 hours, preferably 0.5 hours, at 100 to 125 °C, preferably at about 117 °C. After cooling to ambient temperature the iron salt is filtered off and the solvent is distilled off. The residue is taken up in a solvent or mixture of solvents, for example ethyl acetate or dichloromethane/ methanol 9/1 and semisaturated NaCl solution, and filtered through kieselgur, for example. The organic phase is dried and evaporated down. The residue (compound (A4)) may be purified by chromatography or by crystallisation or used as the crude product in Step 3A of the synthesis.

Step 3A

The compound obtained in Step 2A (A4) may be reacted by electrophilic substitution as shown in Diagram 3A to obtain the compound of Formula (A5).

Diagram 3A




In Step 3A 1 equivalent of the amide of Formula (A4) is dissolved in an organic solvent, for example dimethylformamide or dimethylacetamide, preferably dimethylacetamide, and cooled to about -5 to 5 °C, preferably 0°C.

Then 0.9 to 1.3 equivalents of sodium hydride and 0.9 to 1.3 equivalents of a methylating reagent, e.g. methyl iodide, are added. The reaction mixture is stirred for 0.1 – 3 hours, preferably about 1 hour, at about 0 to 10 °C, preferably at about 5 °C, and may optionally be left to stand for a further 12 hours at this temperature. The reaction mixture is poured onto ice water and the precipitate is isolated. The residue (compound (A5)) may be purified by chromatography, preferably over silica gel, or by crystallisation, or used as the crude product in step 4A of the synthesis.

Step 4A

The amination of the compound (A5) obtained in Step 3A to yield the compound of Formula (A9) (Diagram 4A) may be carried out using the methods known from the literature, for variants 4.1 A from e.g. (a) M.P.V. Boarland, J.F.W. McOmie *J. Chem. Soc.* 1951, 1218-1221 or (b) F. H. S. Curd, F. C. Rose *J. Chem. Soc.* 1946, 343-348, for variants 4.2 A from e.g. (a) Banks *J. Am. Chem. Soc.* 1944, 66, 1131, (b) Ghosh and Dolly *J. Indian Chem. Soc.* 1981, 58, 512-513 or (c) N. P. Reddy and M. Tanaka *Tetrahedron Lett.* 1997, 38, 4807-4810.

Diagram 4A




For example, in variant 4.1 A, 1 equivalent of the compound (A5) and 1 to 3 equivalents, preferably about 2 equivalents of the compound (A6) are heated without a solvent or in an organic solvent such as for example sulpholane, dimethylformamide, dimethylacetamide, toluene, N-methylpyrrolidone, dimethylsulphoxide or dioxane, preferably sulpholane, for 0.1 to 4 hours, preferably 1 hour, at 100 to 220 °C, preferably at about 160 °C. After cooling, the product (A9) is crystallised by the addition of organic solvents or mixtures of solvents, e.g. diethylether/methanol, ethyl acetate, methylene chloride, or diethylether, preferably diethylether/methanol 9/1, or purified by chromatography.

For example, in variant 4.2 A , 1 equivalent of the compound (A5) and 1 to 3 equivalents of the compound (A6) are stirred with acid, for example 1-10 equivalents of 10-38% hydrochloric acid and/or an alcohol, for example ethanol, propanol, butanol, preferably ethanol, at reflux temperature for 1 to 48 hours, preferably about 5 hours. The product precipitated (A9) is filtered off and optionally washed with water, dried and crystallised from a suitable organic solvent.

For example, in variant 4.3 A , 1 equivalent of the compound (A5) and 1 to 3 equivalents of the compound (A7) are dissolved in a solvent, for example toluene or dioxane and combined with a phosphine ligand, for example 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl and a palladium catalyst, for example tris(dibenzylidene-acetone)-dipalladium(0) and a base, for example caesium carbonate, and refluxed for 1-24 h, preferably 17 h. The reaction mixture is purified for example over silica gel and the product (A8) is isolated from the solution or obtained by suitable crystallisation. The product (A8) is dissolved in a suitable solvent, for example dioxane and mixed with acid, for example semiconcentrated hydrochloric acid, for example in the ratio of solvent to acid of 3: 1. Then the mixture is refluxed for 1 - 48 h, for example 12 h, and the precipitate formed is isolated. If desired the product (A9) is purified by crystallisation.

Step 5A

Diagram 5A



For example, 1 equivalent of the compound (A9) is dissolved with 1 equivalent of an activating reagent, e.g. O-benzotriazolyl-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) and a base, for example 1.5 equivalents of

5 diisopropylethylamine (DIPEA) in an organic diluent, for example dichloromethane, tetrahydrofuran, dimethylformamide, N-methylpyrrolidone, dimethylacetamide, preferably dichloromethane or dimethylformamide. After the addition of 1 equivalent of the amine (A10) the reaction mixture is stirred for 0.1 to 24 hours, preferably about 2 hours at 20°C to 100°C. The product of Formula (A11) is obtained for example by

10 crystallisation or chromatographic purification.

The compounds of general Formula (I) may be synthesised analogously to the following examples of synthesis. The numbering of the Examples corresponds to the numbering used in Table 2. These Examples are, however, intended only as examples of


15 procedures to illustrate the invention further, without restricting the invention to their subject matter.

The preparation of some intermediate compounds used to synthesise the compounds is also described hereinafter.

20

Preparation of the acids

To synthesise the compounds of Examples 94 and 95 of Table 2, first an intermediate compound Z1



is prepared as described hereinafter.

5

50.0 g (0.48 mol) of D-alanine methyl ester x HCl and 49.1 g (0.50 mol) cyclohexanone are placed in 300 mL dichloromethane and then combined with 41.0 g (0.50 mol) sodium acetate and 159.0 g (0.75 mol) sodium triacetoxyborohydride. The mixture is stirred overnight and then 300 mL of 10% sodium hydrogen carbonate solution are added. The aqueous phase is extracted with dichloromethane. The combined organic phases are washed with 10% sodium hydrogen carbonate solution, dried over Na₂SO₄ and evaporated down.

10

Yield: 72.5 g of a compound Z1a (clear liquid)

15

72.5 g of the compound Z1a are placed in 500 mL water and 76.6 g (0.39 mol) of 2,4-dichloro-5-nitropyrimidine in 500 mL diethyl ether are added. At a temperature of -5°C 100 mL 10% potassium hydrogen carbonate solution are added dropwise. The mixture is stirred for 3 h at -5°C and for a further 12 h at ambient temperature. The organic phase is separated off and dried over Na₂SO₄. On evaporation, the product crystallizes out.

20

Yield: 48.0 g of a compound Z1b (yellow crystals)

25

48.0 g of the compound Z1b are dissolved in 350 mL glacial acetic acid and heated to 60°C. 47.5 g of iron powder are added, while the temperature rises to 105°C. The reaction mixture is stirred for three hours at 80°C, then filtered hot through cellulose and evaporated down. The residue is stirred in water and ethyl acetate, suction filtered

and the light-grey precipitate is washed with ethyl acetate. The filtrate is washed with dilute ammonia and water, the organic phase is dried over Na_2SO_4 , filtered through activated charcoal and evaporated down. Some more light-grey solids are obtained. Yield: 29.5 g of a compound Z1c (light-grey crystals)

5

32.1 g of the compound Z1c are placed in 300 mL dimethylacetamide and combined with 13 mL (0.2 mol) methyl iodide. At -5°C 6.4 g (0.16 mol) sodium hydride as a 60% dispersion in mineral oil is added batchwise. After 2 h the reaction mixture is poured onto 800 mL ice water. The precipitate formed is suction filtered and washed with petroleum ether.

10

Yield: 33.0 g of a compound Z1d (beige crystals)


15

4.0 g of the compound Z1d and 2.3 g (15 mmol) 4-amino-3-methylbenzoic acid are suspended in 50 mL ethanol and 120 mL water, combined with 2 mL concentrated hydrochloric acid and refluxed for 48 h. The precipitate formed on cooling is suction filtered and washed with water, ethanol and diethyl ether.

Yield: 2.9 g of a compound Z1 (colourless crystals)

20

To synthesise the compounds Example 188 and Example 203 of Table 2, first of all an intermediate compound Z2



Z2

is prepared as described below.

25

A solution of 128.2 g (0.83 mol) D-alanine ethyl ester x HCl and 71.5 g (0.85 mol) cyclopentanone in 1500 mL dichloromethane is combined with 70.1 (0.85 mol) sodium

acetate and 265.6 g (1.25 mol) sodium triacetoxymethylborohydride. The reaction mixture is stirred for 12 h and then poured into 1.5 L of a 10% sodium hydrogen carbonate solution. The aqueous phase is extracted with dichloromethane. The combined organic phases are dried over Na_2SO_4 and evaporated down.

5 Yield: 143.4 g of a compound Z2a (colourless oil)

66.0 g of the compound Z2a are placed in 500 mL water and combined with 85.0 g (0.44 mol) 2,4-dichloro-5-nitropyrimidine in 500 mL diethyl ether. At -5°C 100 mL 10% potassium hydrogen carbonate solution are added dropwise and the reaction
10 mixture is stirred for 48 h at ambient temperature. The aqueous phase is extracted with diethyl ether, the combined organic phases are dried over Na_2SO_4 and evaporated down. The dark red solid is stirred with petroleum ether and suction filtered.
Yield: 88.0 g of a compound Z2b (yellow crystals)

15 88.0 g of the compound Z2b are dissolved in 1000 mL glacial acetic acid and at 60°C combined batchwise with 85 g iron powder, while the temperature rises to 110°C . It is stirred for 1 h at 60°C , then suction filtered hot through cellulose and evaporated down. The brown solid is stirred with 700 mL water and suction filtered.
Yield: 53.3 g of a compound Z2c (light brown crystals)


20 53.3 g of the compound Z2c are dissolved in 300 mL dimethylacetamide and combined with 13 mL (0.21 mol) methyl iodide. At -5°C 5.0 g (0.21 mol) sodium hydride as a 60% dispersion in mineral oil are added batchwise. After 12 h the reaction mixture is poured onto 1000 mL ice water and the precipitate formed is suction filtered.

25 Yield: 40.0 g of a compound Z2d (colourless crystals)

4.0 g of the compound Z2d and 2.8 g (16 mmol) 4-amino-3-chlorobenzoic acid are suspended in 25 mL ethanol and 60 mL water, combined with 3 mL concentrated hydrochloric acid and refluxed for 43 h. The precipitate formed on cooling is suction
30 filtered and washed with water, ethanol and diethyl ether.

Yield: 0.9 g of a compound Z2 (colourless crystals)

To synthesise the compounds of Examples 19, 21, 22, 23, 45, 46, 55, 58, 116, 128, 131, 133, 134, 136, 138, 177, 217, 231, 239, 46, 184, 166 and 187 of Table 2, first of all an intermediate compound Z3



5 is prepared as described below.

54.0 g (0.52 mol) D-2-aminobutyric acid are suspended in 540 mL methanol and slowly combined with 132 g (1.1 mol) thionyl chloride while cooling with ice. The mixture is refluxed for 1.5 h and then evaporated down. The oil remaining is combined with 540
10 mL tert-butylmethylether and the colourless crystals formed are suction filtered.
Yield: 78.8 g of a compound Z3a (colourless crystals)

74.2 g of the compound Z3a and 43.5 mL (0.49 mol) cyclopentanone are dissolved in 800 mL dichloromethane. After the addition of 40.0 g (0.49 mol) sodium acetate and
15 150.0 g (0.71 mol) sodium triacetoxyborohydride at 0°C the mixture is stirred for 12 h at ambient temperature and then 500 mL of 20% sodium hydrogen carbonate solution are added. The aqueous phase is extracted with dichloromethane. The combined organic phases are washed with water, dried over MgSO₄ and evaporated down.
Yield: 85.8 g of a compound Z3b (light yellow oil)

20

40.0 g of the compound Z3b and 30.0 g (0.22 mol) potassium carbonate are suspended in 600 mL acetone and combined with 45.0 g (0.23 mol) 2,4-dichloro-5-nitropyrimidin in 200 mL acetone while cooling with ice. After 12 h a further 5.0 g 2,4-dichloro-5-nitropyrimidin are added and stirred for 3 h. The reaction mixture is evaporated down,
25 taken up in 800 mL ethyl acetate and 600 mL water and the aqueous phase is extracted

with ethyl acetate. The combined organic phases are washed with water, dried over MgSO_4 and evaporated down.

Yield: 75.0 g of a compound Z3c (brown oil)

5 100 g of the compound Z3c are dissolved in 650 mL glacial acetic acid and at 70°C 20 g of iron powder are added batchwise. The mixture is stirred for 1 h at 70°C, then for 1.5 h at 100°C and then filtered hot through kieselgur. The reaction mixture is evaporated down, taken up in methanol/dichloromethane, applied to silica gel and purified with ethyl acetate by Soxhlet extraction. The solvent is removed and the residue stirred with
10 methanol.

Yield: 30.0 g of a compound Z3d (light brown crystals)

25.0 g of the compound Z3d and 6.5 mL (0.1 mol) methyl iodide are placed in 250 mL dimethylacetamide and at -10°C 3.8 g (0.95 mol) sodium hydride as a 60% dispersion
15 in mineral oil is added. It is stirred for 20 min at 0°C, then for 30 min at ambient temperature and finally ice is added. The reaction mixture is evaporated down and combined with 300 mL water. The precipitate formed is suction filtered and washed with petroleum ether.

Yield: 23.0 g of a compound Z3e (colourless solid)


20

6.0 g of the compound Z3e and 5.1 g (31 mmol) 4-amino-3-methoxybenzoic acid are suspended in 90 mL ethanol and 350 mL water, combined with 3.5 mL concentrated hydrochloric acid and refluxed for 48 h. The reaction mixture is evaporated down, the residue stirred with methanol/diethyl ether and the precipitate formed is suction filtered.

25 Yield: 6.3 g of a compound Z3 (light beige crystals)

To synthesise the compound of Examples 81, 82, 93 and 137 of Table 2, first of all an intermediate compound Z4

30



Z4

5 is prepared as described below.

25.0 g (0.19 mol) of ethyl 1-aminocyclopropane-1-carboxylate x HCl and 16.8 g (0.20 mol) of cyclopentanone are dissolved in 300 mL of dichloromethane and combined with 16.4 g (0.20 mol) of sodium acetate and 61.7 g (0.29 mol) of sodium
10 triacetoxyborohydride. It is stirred overnight and the reaction mixture is then poured onto 400 mL of 10% sodium hydrogen carbonate solution. The aqueous phase is extracted with dichloromethane. The combined organic phases are dried over Na₂SO₄ and evaporated down.

Yield: 34.5 g of a compound Z4a (colourless oil)

15

42.5 g (0.22 mol) of 2,4-dichloro-5-nitropyrimidine in 350 mL of diethyl ether are added to a mixture of 34.5 g of the compound Z4a in 350 mL water. At -5°C the mixture is combined with 80 mL 10% potassium hydrogen carbonate solution and stirred overnight at ambient temperature. The aqueous phase is extracted with diethyl
20 ether. The combined organic phases are dried over Na₂SO₄ and evaporated down.

Yield: 53.8 g of a compound Z4b (brown oil)

20.1 g of the compound Z4b are dissolved in 200 mL glacial acetic acid and combined batchwise at 60°C with 19.1 g iron powder, during which time the temperature rose to
25 100°C. The mixture is stirred for 3 h at 60°C, then suction filtered through cellulose and

evaporated down. The residue is stirred in water and ethyl acetate and the yellow precipitate is suction filtered. The filtrate is washed with dilute ammonia and water, the organic phase dried over Na₂SO₄ and evaporated down. After the addition of diethyl ether additional product crystallised out.

5 Yield: 4.0 g of a compound Z4c (yellow crystals)


7.8 g of the compound Z4c and 2.6 mL (0.04 mol) methyl iodide are dissolved in 100 mL dimethylacetamide and at -5°C 1.5 g (0.04 mol) sodium hydride are added batchwise as a 60% dispersion in mineral oil. After 2 h the reaction mixture is poured
10 onto ice water and the precipitate formed is suction filtered.

Yield: 7.5 g of a compound Z4d (light brown crystals)

3.0 g of the compound Z4d and 1.9 g (11 mmol) 4-amino-3-methoxybenzoic acid are suspended in 40 mL ethanol and 80 mL water, combined with 2 mL concentrated
15 hydrochloric acid and refluxed for 20 h. A further 0.5 g of 4-amino-3-methoxybenzoic acid are added and refluxed for 48 h. The precipitate formed on cooling is suction filtered and washed with water, ethanol and diethyl ether.

Yield: 2.1 g of a compound Z4 (colourless crystals) m.p.: 222-223°C

20 To synthesise the compounds of Examples 162, 43, 53, 161, 202, 211, 215 and 212 of Table 2, first of all an intermediate compound Z5



Z5

is prepared as described below.

A mixture of 73.4 mL (0.5 mol) ethyl 2-bromoisobutyrate, 87.1 mL (0.75 mol) of 3-methyl-1-butylamine, 82.5 g (0.6 mol) sodium iodide and 76.0 g (0.6 mol) of potassium carbonate in 1000 mL ethyl acetate is refluxed for 3 days. Any salts present are filtered off and the filtrate evaporated down.

Yield: 97.0 g of a compound Z5a (red oil)

49.0 g (0.25 mol) of 2,4-dichloro-5-nitropyrimidine and 38.3 g (0.28 mol) of potassium carbonate are suspended in 500 mL acetone and at 0°C combined with 93.0 g of the compound Z5a in 375 mL acetone. The reaction mixture is stirred overnight at ambient temperature, filtered and evaporated down. The residue dissolved in ethyl acetate is washed with water and the organic phase dried over MgSO₄ and evaporated down.

Yield: 102.7 g of a compound Z5b (brown oil)

22.7 g of the compound Z5b are dissolved in 350 mL glacial acetic acid and at 60°C combined batchwise with 17.4 g iron powder. After the addition ends the mixture is refluxed for 0.5 h, filtered hot and evaporated down. The residue is taken up in 200 mL dichloromethane/methanol (9:1) and washed with sodium chloride solution. The organic phase is suction filtered through kieselguhr, dried over MgSO₄, evaporated down and purified by column chromatography (eluant: ethyl acetate/cyclohexane 1:1).

Yield: 1.9 g of a compound Z5c (colourless crystals)

1.9 g of the compound Z5c are dissolved in 32 mL dimethylacetamide and while cooling with ice combined with 0.3 g (7 mmol) sodium hydride as a 60% dispersion in mineral oil. After 10 min 0.5 mL (7 mmol) methyl iodide are added and stirred for 3 h at ambient temperature. The reaction mixture is evaporated down and combined with water. The precipitate formed is suction filtered and washed with petroleum ether.


Yield: 1.6 g of a compound Z5d (colourless crystals)

14.0 g of the compound Z5d and 10.0 g (0.06 mol) 4-amino-3-methoxybenzoic acid are suspended in 200 mL dioxane and 80 mL water, combined with 10 mL concentrated

hydrochloric acid and refluxed for 40 h. The precipitate formed on cooling is suction filtered and washed with water, dioxane and diethyl ether.

Yield: 13.9 g of a compound Z5 (colourless crystals)

- 5 To synthesise the compounds of Examples 88, 194, 229 and 89 of Table 2, first of all an intermediate compound Z6



Z6

- 10 is prepared as described below.

6.0 g (0.06 mol) L-2-aminobutyric acid is placed in 80 mL 0.5 M sulphuric acid and at 0°C combined with 5.5 g (0.08 mol) sodium nitrite in 15 mL water. The reaction mixture is stirred for 22 h at 0°C, combined with ammonium sulphate and filtered. The filtrate is extracted with diethyl ether and the combined organic dried over MgSO₄ and evaporated down.

Yield: 6.0 g of a compound Z6a (yellow oil)

20 200 mL methanol are combined successively with 65.0 mL (0.89 mol) thionyl chloride and 76.0 g of the compound Z6a in 50 mL methanol while cooling with ice. The resulting mixture is stirred for 1 h at 0°C and 2 h at ambient temperature and then the methanol and remaining thionyl chloride are eliminated in vacuo at 0°C.

Yield: 40.0 g of a compound Z6b (yellow oil)

30.0 mL (0.17 mol) of trifluoromethanesulphonic acid anhydride are placed in 150 mL dichloromethane and while cooling with ice a solution of 20.0 g of the compound Z6b and 14.0 mL (0.17 mol) pyridine in 50 mL dichloromethane is added within one hour.

- 5 The mixture is stirred for 2 h at ambient temperature, any salts formed are suction filtered and then washed with 100 mL water. The organic phase is dried over MgSO_4 and evaporated down.

Yield: 42.0 g of a compound Z6c (light yellow oil)

- 10 42.0 g of the compound Z6c in 200 mL dichloromethane is added dropwise within one hour to a solution of 15.5 mL (0.17 mol) of aniline and 24.0 mL (0.17 mol) of triethylamine in 400 mL dichloromethane while cooling with ice. The mixture is stirred for 1 h at ambient temperature and a further 2 h at 35°C. The reaction mixture is washed with water, dried over MgSO_4 and evaporated down. The residue remaining is purified
15 by distillation (95-100°C, $1 \cdot 10^{-3}$ mbar).

Yield: 14.0 of a compound Z6d (colourless oil)

- 14.0 g of the compound Z6d and 16.0 g (0.1 mol) potassium carbonate are suspended in 100 mL acetone and at 10°C combined with 16.0 g (0.08 mol) of 2,4-dichloro-5-
20 nitropyrimidine. The mixture is stirred for 4 h at 40°C, any salts formed are suction filtered and the filtrate evaporated down. The residue is taken up in 300 mL ethyl acetate and washed with water. The organic phase is dried over MgSO_4 and evaporated down.

Yield: 31.0 g of a compound Z6e (brown oil)

25

31.0 g of the compound Z6e are dissolved in 200 mL glacial acetic acid and at 60°C combined batchwise with 10 g iron powder, during which time the temperature rose to 85°C. The mixture is stirred for a further hour at 60°C, filtered through kieselguhr and evaporated down. The residue is stirred with methanol.

- 30 Yield: 4.5 g of a compound Z6f (brown crystals)

At -20°C 0.6 g (16 mmol) of sodium hydride as a 60% dispersion in mineral oil are added batchwise to a mixture of 4.5 g of the compound Z6f and 1.0 mL (16 mmol)

methyl iodide in 100 mL dimethylacetamide. After 1 h the reaction mixture is combined with 50 mL water and evaporated down. The residue is stirred with 200 mL water, the precipitate is suction filtered and washed with petroleum ether.

Yield: 4.5 g of a compound Z6g (colourless crystals)

5

A suspension of 1.5 g of the compound Z6g and 1.4 g (8 mmol) of methyl 4-amino-3-methoxybenzoate in 30 mL toluene is combined with 0.4 g (0.6 mmol) of 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl, 0.23 g (0.3 mmol) of tris(dibenzylideneacetone)-dipalladium(0) and 7.0 g (21 mmol) of caesium carbonate and refluxed for 17 h. The


10 reaction mixture is applied to silica gel and purified by column chromatography (eluant: dichloromethane/methanol 9:1).

Yield: 1.7 g of a compound Z6h (yellow crystals)

1.7 g of the compound Z6h are dissolved in 50 mL dioxane, combined with 15 mL of
15 semiconcentrated hydrochloric acid and refluxed for 12 h. After cooling the precipitate formed is suction filtered.

Yield: 1.1 g of a compound Z6 (colourless solid)

To synthesise the compounds of Examples 26, 20, 32, 56, 101, 112 and 209 of Table 2,
20 first of all an intermediate compound Z7



is prepared as described below.

50.0 g (0.36 mol) D-alanine methyl ester x HCl is suspended in 500 mL of
5 dichloromethane and 35 mL of acetone and combined with 30.0 g (0.37 mol) of sodium acetate and 80.0 g (0.38 mol) of sodium triacetoxyborohydride. The mixture is stirred for 12 h and then poured onto 400 mL of 10% sodium hydrogen carbonate solution. The organic phase is dried over Na₂SO₄ and evaporated down.

Yield: 51.0 g of a compound Z7a (yellow oil)

10

A suspension of 51.0 g of the compound Z7a in 450 mL water is combined with 80.0 g (0.41 mol) of 2,4-dichloro-5-nitropyridine in 450 mL of diethyl ether. At -5°C 100 mL of 10% potassium hydrogen carbonate solution are added dropwise. The reaction mixture is stirred for 3 h, the organic phase dried over Na₂SO₄ and evaporated down.

15 Yield: 74 g of a compound Z7b (yellow oil)

18.6 g of the compound Z7b are dissolved in 200 mL glacial acetic acid and at 60°C combined batchwise with 20.0 g iron powder. The mixture is stirred for 2 h at 60°C and then suction filtered through cellulose. The residue is dissolved in ethyl acetate and
20 washed with water and concentrated ammonia. The organic phase is dried over Na₂SO₄ and evaporated down. The residue is crystallised from diethyl ether.

Yield: 9.8 g of a compound Z7c (colourless crystals)

17.0 g of the compound Z7c and 7 mL (0.1 mol) methyl iodide are dissolved in 200 mL
25 dimethylacetamide and at -5°C combined with 4.0 g (0.1 mol) of sodium hydride as a 60% dispersion in mineral oil. The reaction mixture is stirred for 30 min and then poured onto 300 mL ice water. The precipitate formed is suction filtered and stirred with petroleum ether.

Yield: 14.8 g of a compound Z7d (beige crystals)





30

0.9 g of the compound Z7d and 1.5 g (9 mmol) 4-amino-3-methoxybenzoic acid are heated to 210°C for 30 min. After cooling the residue is stirred with ethyl acetate and the precipitate obtained is suction filtered.

Yield: 1.2 g of a compound Z7 (grey crystals)

The following acids can, for example, be prepared analogously to the methods of synthesis hereinbefore described.

5





10 Synthesis of the amino components L-R5

The following amines,

1,1-dimethyl-2-dimethylamino-1-yl-ethylamine and 1,1-dimethyl-2-piperidin-1-yl-ethylamine,

15 ethylamine,




may be obtained as follows.

The compounds may be prepared according to the following references: (a) S. Schuetz
5 et al. *Arzneimittel-Forschung* **1971**, 21, 739-763, (b) V. M. Belikov et al. *Tetrahedron*
1970, 26, 1199-1216 and (c) E.B. Butler and McMillan *J. Amer. Chem. Soc.* **1950**, 72,
2978.

Other amines can be prepared as follows, in a modified manner compared with the
10 literature described above.


1,1-dimethyl-2-morpholin-1-yl-ethylamine





15 8.7 mL morpholine and 9.3 mL 2-nitropropane are prepared while cooling the reaction
with ice, 7.5 mL formaldehyde (37%) and 4 mL of a 0.5 mol/L NaOH solution are
slowly added dropwise (<10°C). Then the mixture is stirred for 1h at 25°C and 1h at
50°C. The solution is treated with water and ether and the aqueous phase is extracted 3x
with ether. The combined organic phase is dried over NaSO₄ and combined with HCl in
20 dioxane (4mol/l), the precipitate formed is suction filtered. Yield: 21.7 of white powder
5 g of the white powder are dissolved in 80 mL methanol and with the addition of 2 g
RaNi treated with hydrogen at 35°C and 50 psi for 40 minutes. This yields 3.6 g of 1,1-
dimethyl-2-morpholin-1-yl-ethylamine.

25 The following amines can be prepared analogously.


1,1- dimethyl-N-methylpiperazin-1-yl-ethylamine




1,1-dimethyl-2-pyrrolidin-1-yl-ethylamine1,3 -dimorpholin-2-amino-propane

5

5 g of 1,3 Dimorpholine-2-nitropropane obtained from Messrs. Aldrich is dissolved in 80 mL methanol and treated with hydrogen for 5.5 h at 30°C and 50 psi with the addition of 2 g RaNi. This yields 4.2 g of 1,3 dimorpholin-2-amino-propane.

10 4-Aminobenzylmorpholine

The preparation of this amine is described in the following reference:
S. Mitsuru et al. *J. Med. Chem.* 2000, 43, 2049-2063.

15 4-amino-1-tetrahydro-4H-pyran-4-yl-piperidine

20 g (100 mmol) of 4-tert-butyloxycarbonyl-aminopiperidine are dissolved in 250 mL CH_2Cl_2 and stirred for 12 h at RT with 10 g (100 mmol) tetrahydro-4H-pyran-4-one and 42 g (200 mmol) $\text{NaBH}(\text{OAc})_3$. Then water and potassium carbonate are added, the organic phase is separated off, dried and the solvent is eliminated in vacuo. The residue
 5 is dissolved in 200 mL CH_2Cl_2 and stirred for 12 h at RT with 100 mL trifluoroacetic acid. The solvent is eliminated in vacuo, the residue taken up with CHCl_3 and evaporated down again, then taken up in acetone and the hydrochloride is precipitated with ethereal HCl. Yield: 14.3 g (56%).

10 Cis- and trans-4-morpholino-cyclohexylamine



Dibenzyl-4-morpholino-cyclohexylamine

15 3.9 g (30 mmol) of 4-dibenzylcyclohexanone are dissolved in 100 mL of CH_2Cl_2 and stirred for 12 h at RT with 3.9 g (45 mmol) of morpholine and 9.5 g (45 mmol) $\text{NaBH}(\text{OAc})_3$. Then water and potassium carbonate are added, the organic phase is separated off, dried and the solvent is eliminated in vacuo. The residue is purified through a silica gel column (about 20 mL silica gel; about 500 mL of ethyl acetate 90/
 20 methanol 10 + 1% concentrated ammonia). The appropriate fractions are evaporated down in vacuo. Yield : 6.6 g (60%) of cis-isomer and 2 g (18%) of trans-isomer.

Alternatively, the trans-dibenzyl-4-morpholino-cyclohexylamine may be prepared by the following method:

25

33 g (112 mmol) of 4-dibenzylcyclohexanone are dissolved in 300 mL MeOH, combined with 17.4 g (250 mmol) of hydroxylamine hydrochloride and stirred for 4 h at 60°C. The solvent is evaporated down in vacuo, combined with 500 mL water and 50 g potassium carbonate and extracted twice with 300 mL of dichloromethane. The organic

phase is dried, evaporated down in vacuo, the residue is crystallised from petroleum ether, dissolved in 1.5 L of EtOH and heated to 70°C. 166 g of sodium are added batchwise and the mixture is refluxed until the sodium dissolves. The solvent is eliminated in vacuo, the residue combined with 100 mL water and extracted twice with 400 mL of ether. The organic phase is washed with water, dried, evaporated down in vacuo and the *trans* isomer is isolated using a column (about 1.5 L silica gel; about 2 L of ethyl acetate 80/ methanol 20 + 2 % concentrated ammonia). Yield: 12.6 g (41.2%).

6.8 g (23 mmol) of trans-1-amino-4-dibenzylaminocyclohexane is dissolved in 90 mL of DMF and stirred for 8 h at 100°C with 5 mL (42 mmol) of 2,2'-dichloroethyl ether and 5 g of potassium carbonate. After cooling 30 mL of water is added, the precipitated crystals are suction filtered and purified through a short column (about 20 mL silica gel, about 100 mL ethyl acetate). The residue is crystallised from methanol and concentrated HCl as the dihydrochloride. Yield: 7.3 g (72.4%).

15


Trans-4-morpholino-cyclohexylamine

7.2 g (16.4 mmol) of trans-dibenzyl-4-morpholino-cyclohexylamine are dissolved in 100 mL of MeOH and hydrogenated on 1.4 g of Pd/C (10%) at 30-50°C. The solvent is eliminated in vacuo and the residue is crystallised from ethanol and concentrated HCl. Yield: 3.9 g (93%).

20

The *cis* isomer may be prepared analogously.

25 Cis- and trans-4-piperidino-cyclohexylamine



Trans-dibenzyl-4-piperidino-cyclohexylamine

2.0 g (6.8 mmol) of trans-1-amino-4-dibenzylaminocyclohexane (see Example 2) is dissolved in 50 mL DMF and stirred for 48 h at RT with 1.6 g (7 mmol) of 1,5-dibromopentane and 2 g of potassium carbonate. The mixture is cooled, combined with water, extracted twice with 100 mL of dichloromethane, dried and the solvent is eliminated in vacuo. The residue is purified over a column (about 100 mL silica gel, about 500 mL ethyl acetate 80/methanol 20 +1% concentrated ammonia). The desired fractions are evaporated down in vacuo and crystallised from petroleum ether. Yield: 1.2 g (49%).


10 Trans-4-piperidino-cyclohexylamine

1.7 g (4.8 mmol) of trans-dibenzyl-4-piperidino-cyclohexylamine are dissolved in 35 mL MeOH and hydrogenated on 350 mg of Pd/C (10%) at 20°C. The solvent is eliminated in vacuo and the residue crystallised from ethanol and concentrated HCl. Yield: 1.1 g (78%).

The *cis* isomer may be prepared analogously.

Cis- and trans-4-(4-phenyl-piperazin-1-yl)-cyclohexylamine

20




4.1 g (25.3 mmol) of 4-dibenzylcyclohexanone is dissolved in 50 mL of dichloromethane and stirred for 12 h at RT with 7.4 g (25.3 mmol) of N-phenylpiperazine and 7.4 g (35 mmol) of NaBH(OAc)₃. Then water and potassium carbonate are added, the organic phase is separated off, dried and the solvent is eliminated in vacuo. The residue is purified over a silica gel column (ethyl acetate 80/ methanol 20 + 0.5% concentrated ammonia). Yield: 1.7 g (15.8%) of cis-isomer and 0.27 (2.5%) of trans-isomer.

30 Trans-4-(4-phenyl-piperazin-1-yl)-cyclohexylamine

270 mg (0,61 mmol) of trans-dibenzyl-[4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-amine are dissolved in 5 mL MeOH and hydrogenated on 40 mg of Pd/C (10%) at 20-30 °C. The solvent is eliminated in vacuo and the residue crystallised from ethanol and concentrated HCl. Yield: 110 mg (69%).

The cis isomer may be prepared analogously.

Cis- and trans-4-(4-cyclopropylmethyl-piperazin-1-yl)-cyclohexylamine



9.8 g (33.4 mmol) of 4-dibenzylcyclohexanone is dissolved in 100 mL dichloromethane and stirred for 12 h at RT with 5.6 g (40 mmol) of N-cyclopropylmethylpiperazine and 8.5 g (40 mmol) of NaBH(OAc)₃. Then water and potassium carbonate are added, the organic phase is separated off, dried and the solvent is eliminated in vacuo. The residue is purified over a silica gel column (about 50 mL silica gel, about 3 L ethyl acetate 95/ methanol 5 + 0.25% concentrated ammonia. The appropriate fractions are evaporated down in vacuo. The faster eluting cis compound crystallised from ethyl acetate. The trans-compound is crystallised from ethanol + concentrated HCl. Yield: 8.5 g (61%) cis-isomer and 2.2 (13%) trans-isomer.

cis-4-(4-cyclopropylmethyl-piperazin-1-yl)-cyclohexylamine

8.5 g (20 mmol) of cis-dibenzyl-[4-(4-cyclopropylmethyl-piperazin-1-yl)-cyclohexyl]-amine are dissolved in 170 mL MeOH and hydrogenated on 1.7 g Pd/C (10%) at 30-50 °C. The solvent is eliminated in vacuo and the residue is crystallised from ethanol and concentrated HCl. Yield: 4.4 g (91%).

The trans-isomer may be prepared analogously.

Synthesis of the Examples

Example 152

5

0.15g of the compound Z10, 0.14 g TBTU, 0.13 mL DIPEA are dissolved in dichloromethane and stirred for 20 minutes at 25°C. Then 90 μ L 1-(3-aminopropyl)-4-methylpiperazine is added and stirred for a further 2 hours at 25°C. The solution is then diluted with dichloromethane and extracted with water. The product is precipitated by the addition of petroleum ether, ether and ethyl acetate to the organic phase. Yield: 0.16 g of beige solid.

Example 164

15 0.10g of the compound Z10, 0.1 g TBTU, 0.08 mL DIPEA are dissolved in 4 mL dichloromethane and stirred for 20 minutes at 25°C. Then 44 μ L dimethylaminopropylamine are added and stirred for a further 2 hours at 25°C. The solution is then diluted with dichloromethane and extracted with water. The product is precipitated by the addition of petroleum ether, ether and acetone to the organic phase.

20 Yield: 0.08 g yellow solid.

Example 242

0.15g of the compound Z10, 0.14 g TBTU, 0.13 mL DIPEA are dissolved in 5 mL dichloromethane and stirred for 20 minutes at 25°C. Then 75 μ L 1-(2-aminoethyl) piperidine are added and stirred for a further 2 hours at 25°C. The solution is then diluted with dichloromethane and extracted with water. The product is precipitated by the addition of petroleum ether, ether and ethyl acetate to the organic phase. Yield: 0.14 g yellow solid.

30

Example 188

0.1 g of the compound Z2, 0.09 g TBTU, 0.05 mL DIPEA are dissolved in 15 mL dichloromethane and stirred for 20 minutes at 25°C. Then 33 mg 1-methyl-4-aminopiperidin are added and the mixture is stirred for a further 3 hours at 25°C. The solution is extracted with 20 mL water, then evaporated down in vacuo. The product is
5 crystallised using ether. Yield: 0.047 g of white crystals.

Example 203

0.1 g of the compound Z2, 0.09 g TBTU, 0.5 mL DIPEA are dissolved in 15 mL dichloromethane and stirred for 30 minutes at 25°C. Then 50 mg 4-amino-1-benzylpiperidin are added and the mixture is stirred for a further 3 hours at 25°C. The solution is extracted with 20 mL water, then evaporated down in vacuo. Then the residue is chromatographed over silica gel and the isolated product is crystallised with
10 ether. Yield: 0.015 g of white crystals.

15

Example 94

0.17 g of the compound Z1, 0.19 g TBTU, 0.11 mL DIPEA are dissolved in 50 mL dichloromethane and stirred for 30 minutes at 25°C. Then 63 mg of 1-methyl-4-aminopiperidine are added and the mixture is stirred for a further 17 hours at 25°C. 50 mL of water and 1 g of potassium carbonate are added to the solution and the organic phase is separated off using a phase separation cartridge, then evaporated down in vacuo. Then the product is purified by silica gel chromatography and the purified product is crystallised with ether. Yield: 0.1 g of white crystals.
20

25

Example 95

0.17 g of the compound Z1, 0.19 g TBTU, 0.11 mL DIPEA are dissolved in 50 mL dichloromethane and stirred for 30 minutes at 25°C. Then 77 mg of exo-3- β -amino-tropane are added and the mixture is stirred for a further 17 hours at 25°C. 50 mL of water and 1 g of potassium carbonate are added to the solution and the organic phase is separated off using a phase separation cartridge, then evaporated down in vacuo. Then
30

the product is purified by silica gel chromatography and the purified product is crystallised with ether. Yield: 0.03 g of white crystals.

Example 46

5

0.15 g of the compound Z3, 0.12 g TBTU, 0.12 mL DIPEA are dissolved in 5 mL dichloromethane and stirred for 30 minutes at 25°C. Then 50 mg 1-methyl-4-aminopiperidin are added and the mixture is stirred for a further 2.5 hours at 25°C. The solution is then extracted with water and then evaporated down. The residue is dissolved in warm ethyl acetate and crystallised from ether and petroleum ether. Yield: 0.025 g of white crystals.

Example 80

0.2 g of the compound Z8, 0.2 g of TBTU, 0.1 mL of DIPEA are dissolved in 10 mL dichloromethane and stirred for 30 minutes at 25°C. Then 100 mg of 1-methyl-4-aminopiperidine are added and the mixture is stirred for a further 17 hours at 25°C. The solution is then extracted with a dilute potassium carbonate solution and evaporated down. The residue is crystallised using ether. Yield: 0.12 g of white crystals.

20

Example 190

0.2 g of compound Z8, 0.2 g of TBTU, 0.3 mL of DIPEA are dissolved in 5 mL dichloromethane and stirred for 1h at 25°C. Then 0.13 g of 4-amino-1-benzylpiperidine are added and the mixture is stirred for a further hour at 25°C. The solution is then diluted with 10 mL methylene chloride and extracted with 20 mL water. Then the product is purified over silica gel and crystallised from ethyl acetate and ether. Yield: 0.23 g of the compound Z8.

0.23 g of the benzylamine Z8 are dissolved in 10 mL methanol, combined with 50 mg of Pd/C and hydrogenated under 3 bar for 3h at 25°C. By adding petroleum ether and ethyl acetate white crystals are produced. These are chromatographed over silica gel and crystallised from ethyl acetate and ether. Yield: 0.075 g of white crystals.

30

Example 196

0.1g of compound Z10, 0.09 g of TBTU, 0.3 mL of DIPEA are dissolved in 4 mL of dichloromethane and stirred for 20 minutes at 25°C. Then 67 mg xx amine is added and stirred for a further 2 hours at 25°C. The solution is then diluted with dichloromethane and extracted with water. It is then chromatographed over silica gel and the residue is dissolved in acetone, combined with ethereal HCl and the precipitate formed is isolated. Yield: 0.09 g light yellow solid.

10 Example 166

0.1 g of the compound Z10, 0.11 g of TBTU, 0.14 mL of DIPEA are dissolved in 2 mL dimethylformamide and stirred for 3h at 50°C. Then 55 mg of 4-morpholinomethylphenylamine is added. The reaction mixture is then cooled to ambient temperature within 17 h. Then the dimethylformamide is eliminated in vacuo, the residue is taken up in dichloromethane and extracted with water. It is then chromatographed over silica gel and the product crystallised from ethyl acetate and ether. Yield: 0.06 g yellowish crystals.

20 Example 81

0.2 g of the compound Z4, 0.2 g of TBTU, 0.1 mL of DIPEA are dissolved in 10 mL dichloromethane and stirred for 30 minutes at 25°C. Then 0.1 g of 1-methyl-4-aminopiperidine are added and the mixture is stirred for a further 17 hours at 25°C. The solution is then extracted with aqueous potassium carbonate solution and then evaporated down. The product is crystallised using ether. Yield: 0.16 g of white crystals.

Example 162

30

0.1 g of the compound Z5, 0.07 g of TBTU, 0.15 mL of DIPEA are dissolved in 5 mL dichloromethane and stirred for 20 minutes at 25°C. Then 0.04 g 1-methyl-4-aminopiperidine are added and the mixture is stirred for a further 2 hours at 25°C. The

solution is then diluted with 15 mL dichloromethane and extracted with 20 mL water. The residue is dissolved in MeOH and acetone, combined with 1 mL ethereal HCl and evaporated down. A crystalline product is produced using ether, ethyl acetate and a little MeOH. Yield: 0.1 g of white crystals.

5

Example 88

0.1 g of the compound Z6, 0.12 g of TBTU, 0.12 mL of DIPEA are in 10 mL dichloromethane dissolved and stirred for 30 minutes at 25°C. Then 0.04 g of 1-methyl-4-aminopiperidine are added and the mixture is stirred for a further 2 hours at 25°C. The solution is then diluted with 10 mL dichloromethane and extracted with 10 mL water. A crystalline product is produced using ether, ethyl acetate and petroleum ether. Yield: 0.6 g of white crystals.

15 Example 89

0.1 g of the compound Z6, 0.08 g of TBTU, 0.08 mL of DIPEA are dissolved in 10 mL dichloromethane and stirred for 30 minutes at 25°C. Then 37 μ L g N,N-dimethylneopentanediamine are added and the mixture is stirred for a further 2 hours at 25°C. The solution is then diluted with 10 mL dichloromethane and extracted with 10 mL water. The product is then chromatographed over silica gel and crystallised from ethyl acetate, ether and petroleum ether. Yield: 0.005 g of white crystals.

Example 26

25

0.15 g of the compound Z7, 0.16 g of TBTU, 1 mL of DIPEA are dissolved in 5 mL dichloromethane and stirred for 30 minutes at 25°C. Then 0.1 g 4-morpholinocyclohexylamine are added and the mixture is stirred for a further 17 hours at 25°C. The residue is then combined with 10 mL of 10% potassium carbonate solution, the precipitate is isolated and washed with water. It is then dissolved in dichloromethane and evaporated down again. The product is crystallised from ethyl acetate. Yield: 0.1 g of white crystals.

30

Example 9

150 mg of the compound Z9 and 93 mg of amine are dissolved in 5 mL dichloromethane and stirred with 160 mg of TBTU and 1 mL of DIPEA for 12 h at RT .

- 5 The solvent is eliminated in vacuo, the residue is combined with 10 mL of 10% potassium carbonate solution. The precipitate is suction filtered, washed with water, taken up in dichloromethane, dried and the solvent eliminated in vacuo. The residue is crystallised from ethyl acetate. Yield: 82.0 mg.

10 Example 16

- 150 mg of the compound Z8 and 73 mg of trans-4-piperidino-cyclohexylamine are dissolved in 5 mL dichloromethane and stirred with 160 mg (0.50 mmol) of TBTU and 1 mL of DIPEA for 12 h at RT. The solvent is eliminated in vacuo, the residue is
15 combined with 10 mL of 10% potassium carbonate solution. The precipitate is suction filtered, washed with water, taken up in dichloromethane, dried and the solvent eliminated in vacuo. The residue is crystallised from ethyl acetate. Yield: 87.0 mg.

Example 37

20

- 100 mg of the compound Z9 and 42 mg of 3-amino-1-ethyl-pyrrolidine are dissolved in 10 mL dichloromethane and stirred with 90 mg of TBTU and 0.5 mL of DIPEA for 12 h at RT. The solvent is eliminated in vacuo, the residue is combined with 10 mL of 10% potassium carbonate solution. The precipitate is suction filtered, washed with water,
25 taken up in dichloromethane, dried and the solvent is eliminated in vacuo. The residue is crystallised from ethyl acetate/petroleum ether. Yield: 24.0 mg .

Example 120

- 30 100 mg of the compound Z11 and 73 mg of 4-amino-1-tetrahydro-4H-pyran-4-yl-piperidine are dissolved in 10 mL dichloromethane and stirred with 90 mg of TBTU and 0.5 mL of DIPEA for 1 h at RT. The solvent is eliminated in vacuo, the residue is

combined with 10 mL of 10% potassium carbonate solution. The precipitate is suction filtered, washed with water, taken up in dichloromethane, dried and the solvent is eliminated in vacuo. The residue is crystallised from ethyl acetate/petroleum ether. Yield: 89 mg.

5

Example 212

150 mg of the compound Z5 and 150 mg of trans-4-(4-cyclopropylmethyl-piperazin-1-yl)-cyclohexylamine (as the hydrochloride) are dissolved in 5 mL of dichloromethane and stirred with 160 mg of TBTU and 2 mL of DIPEA for 2 h at RT. The solvent is eliminated in vacuo, the residue is combined with 10 mL of 10% potassium carbonate solution. The precipitate is suction filtered, washed with water, taken up in dichloromethane, dried and the solvent eliminated in vacuo. The residue is purified over a column (20 mL silica gel, 300 mL ethyl acetate 90/ methanol 10 + 2% concentrated ammonia). The appropriate fractions are evaporated down in vacuo and crystallised from ethyl acetate. Yield: 140 mg.

Example 232

390 mg of the compound Z11 and 240 mg of trans-4-(4-tbutoxycarbonyl-piperazin-1-yl)-cyclohexylamine are dissolved in 2.5 mL of NMP and stirred with 482 mg of TBTU and 1 mL triethylamine for 2 h at RT. Then 100 mL of water and 200 mg of potassium carbonate are added, the precipitate is suction filtered, washed with water and purified through a silica gel column. The appropriate fractions are evaporated down in vacuo, dissolved in 2 mL dichloromethane, combined with 2 mL of trifluoroacetic acid and stirred for 2 h at RT, combined with another 100ml of water and 200 mg potassium carbonate and the precipitate is suction filtered and washed with water. Then the precipitate is purified through a silica gel column. The appropriate fractions are evaporated down in vacuo and the residue is crystallised from ethanol and concentrated hydrochloric acid. Yield: 95 mg.

Example 213

60 mg of the compound of Example 232 is dissolved in 10 mL ethyl acetate and stirred with 1 mL of acetic anhydride and 1 mL of triethylamine for 30 min. at RT. The solvent is eliminated in vacuo, the residue combined with water and ammonia, the crystals precipitated are suction filtered and washed with water and a little cold acetone.

5 Yield: 40 mg.



















Example 218



















1.2 g of the compound Z9 and 0.5g of 1,4-dioxaspiro[4.5]dec-8-ylamine
10 were dissolved in 20 mL dichloromethane and stirred with 1.28 g of TBTU and 4 mL of triethylamine for 12 h at RT. Then 50 mL of water and 0.5 g of potassium carbonate are added, the organic phase is separated off, dried and evaporated down in vacuo. The residue is crystallised from ethyl acetate, combined with 25 mL of 1 N hydrochloric acid and 20 mL of methanol and stirred for 30 min at 50°C. The methanol is eliminated
15 in vacuo, the precipitate is suction filtered, washed with water and dried. The residue is taken up in 20 mL dichloromethane, stirred with 0.5 g of thiomorpholine and 0.5 g of NaBH(OAc)₃ for 12 h at RT. Then water and potassium carbonate are added, the organic phase is separated off, dried and the solvent is eliminated in vacuo. The residue is purified over a silica gel column. The appropriate fractions are
20 evaporated down in vacuo and the hydrochloride is precipitated with ethereal HCl. Yield: 86 mg of trans-isomer; amorphous powder.




















Example 187

















25 200 mg of the compound Z3 in 5 mL dichloromethane is combined with 0.1 mL of diisopropylethylamine and 180 mg of TBTU and stirred for 30 min. Then 191 mg of 4-(4-methyl-piperazin-1-yl)-phenylamine are added and the mixture is stirred overnight. The reaction mixture is combined with water and the aqueous phase extracted with dichloromethane. The combined organic phases are dried over Na₂SO₄ and evaporated
30 down. The residue is purified by column chromatography (eluant: dichloromethane/methanol 100:7). Yield: 128 mg (light yellow crystals).



















The compounds of Formula (I) listed in Table 2, *inter alia*, are obtained analogously to the procedure described hereinbefore. The abbreviations X₁, X₂, X₃, X₄ and X₅ used in Table 2 in each case denote a link to a position in the general Formula shown under Table 2 instead of the corresponding groups R¹, R², R³, R⁴ and L-R⁵.











4	H		R		H	
5	H		R			
6	H		R			
7	H		R			
8	H		R		H	
9	H		R			












16	H		R			
17	H		R			
18	H		R		H	
19	H		R			
20	H		R			
21	H		R			



















22	H		R			
23	H		R			
24	H		R			
25	H		R			
26	H		R			
27	H		R			

















28	H		R			
29	H		R			
30	H		R			
31	H		R		H	
32	H		R			
33	H		R		H	























34	H		R			
35	H		R			
36	H		R			
37	H		R			
38	H		R			
39	H		R		H	
















40	H	X_2  CH ₃	R	 X_3	X_4 O CH ₃	
41	H	X_2  CH ₃	R	 X_3	CH ₃ O X_4	
42	H	X_2  CH ₃	R	 X_3	CH ₃ O X_4	
43	X_1 CH ₃	X_2  CH ₃		 X_3	H ₃ C O X_4	
44	H	X_2  CH ₃	R	 X_3	H	
45	H	X_2  CH ₃	R	 X_3	H ₃ C O X_4	
















46	H		R			
47	H		R		H	
48	H		R		H	
49	H		R			
50	H		R			


















51	H		R			
52	H		R			
53						
54	H		R			
55	H		R			
56	H		R			











57	H		R			
58	H		R			
59	H		R			
60	H		R			
61						
62	H		R			












63	H		R			
64	H		R			
65	H		R			
66	H		R			
67	H		R			
68	H		R		H	
69	H		R		H	















70	H		R		H	
71	H		R			
72	H		R			
73	H		R		H	
74	H		R			
75	H		R			
















76	H		R			
77	H		R		H	
78	H		R		H	
79	H		R		H	
80	H		R			
81	H		R			
















82	H		R			
83	H		R			
84	H		R			
85	H		R		H	
86	H		R			
87	H		R			

88	H		R				
89	H		R				
90	H		R				
91	H		R				
92	H		R		H		
93	H		R		H		


















94	H	X_2  CH ₃	R		H_3C-X_4	
95	H	X_2  CH ₃	R		H_3C-X_4	
96	H	X_2  CH ₃	R		H_3C-O-X_4	
97	H	X_2  CH ₃	R		H_3C-O-X_4	
98	H	X_2  CH ₃	R		X_4-O-CH_3	
99	H	X_2  CH ₃	R		X_4-O-CH_3	



















100	H		R			
101	H		R			
102	H		R			
103	H		R			
104	H		R			


















105	H	X_2  CH ₃	R			
106	H	X_2  CH ₃	R			
107	H	X_2  CH ₃	R			
108	H	X_2  CH ₃	R			
109	H	X_2  CH ₃	R			























110	H		R			
111	H		R			
112	H		R			
113	H		R			
114	H		R			

115	H		R			
116	H		R			
117	H		R			
118	H		R			
119	H		R			
120	H		R			

















121	H		R			
122	H		R			
123	H		R			
124	H		R			
125	H		R			
126	H		R			



















127	H		R			
128	H		R			
129	H		R			
130	H		R			
131	H		R			
132	H		R			



















133	H		R			
134	H		R			
135	H		R			
136	H		R			
137	H		R			
138	H		R			


















139	H		R				
140	H		R				
141	H		R				
142	H		R				
143	H		R			H	
144	H		R			H	

145	H		R				
146	H		R				
147	H		R				
148	H		R				
149	H		R				
150	H		R				



















151	H		R			
152	H		R			
153	H		R			
154	H		R		H	
155	H		R		H	
156	H		R			






















157	H		R			
158	H		R			
159	H		R			
160	H		R			
161	X ₁ -CH ₃					
162	X ₁ -CH ₃					

















163	H		R			
164	H		R			
165	H		R			
166	H		R			
167	H		R			
168	H		R			













169	H		R			
170	H		R			
171	H		R			
172	H		R			
173	H		R			
174	H		R			
















175	H		R			
176	H		R			
177	H		R			
178	H		R			
179	H		R			
180	H		R			

















181	H		R			
182	H		R			
183	H		R			
184	H		R			
185	H		R			
186	H		R			

















187	H		R			
188	H		R			
189	H		R			
190	H		R			
191	H		R			
192	H		R			









193	H		R			
194	H		R			
195	H		R			
196	H		R			
197	H					
198	H		R			

















					
					
					
	R	R	R		R
					
	H	H	H		H
199					
200					
201					
202					
203					

204	H	X_2  CH ₃	R			
205	H	X_2  CH ₃	R			
206	H	X_2  CH ₃	R			
207	H	X_2  CH ₃	R			
208	H	X_2  CH ₃	R			







209	H		R			
210	H		R			
211	X1-CH3					
212	X1-CH3					
213	H		R			

214	H		R			
215	X_1-CH_3					
216	H		R			
217	H		R			
218	H		R			

225	H		R				
226	H		R				
227	H		R				
228	H		R				
229	H		R				

230	H		R			
231	H		R			
232	H		R			
233	H		R			
234	H		R			
235	H		R			


236	H		R			
237	H		R			
238	H		R			
239	H		R			
240	H		R			
241	H		R			

242	H		R				
243	H		R				
244	H		R				

Claims

1. Use of a compound of Formula (I)

5



wherein

- 10 R^1, R^2 which may be identical or different, denote hydrogen or optionally substituted C_1 - C_6 -alkyl,

or

R^1 and R^2 together denote a 2- to 5-membered alkyl bridge which may contain 1 to 2 heteroatoms,

15

R^3 denotes hydrogen or a group selected from among optionally substituted C_1 - C_{12} -alkyl, C_2 - C_{12} -alkenyl, C_2 - C_{12} -alkynyl and C_6 - C_{14} -aryl, or

a group selected from among optionally substituted and/or bridged C_3 - C_{12} -cycloalkyl,

C_3 - C_{12} -cycloalkenyl, C_7 - C_{12} -polycycloalkyl, C_7 - C_{12} -polycycloalkenyl, C_5 - C_{12} -

- 20 spirocycloalkyl, C_3 - C_{12} -heterocycloalkyl which contains 1 to 2 heteroatoms, and

C_3 - C_{12} -heterocycloalkenyl which contains 1 to 2 heteroatoms, or

R^1 and R^3 or R^2 and R^3 together denote a saturated or unsaturated C_3 - C_4 -alkyl bridge which may contain 1 heteroatom,

R^4 denotes a group selected from among hydrogen, -CN, hydroxy, -NR₆R₇ and halogen,
or

a group selected from among optionally substituted C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-
5 alkynyl, C₁-C₅-alkyloxy, C₂-C₅-alkenyloxy, C₂-C₅-alkynyloxy, C₁-C₆-alkylthio, C₁-C₆-
alkylsulphoxo and C₁-C₆-alkylsulphonyl,

L denotes a linker selected from among optionally substituted C₂-C₁₀-alkyl, C₂-
C₁₀-alkenyl, C₆-C₁₄-aryl, -C₂-C₄-alkyl-C₆-C₁₄-aryl, -C₆-C₁₄-aryl-C₁-C₄-alkyl, optionally
10 bridged C₃-C₁₂-cycloalkyl and heteroaryl which contains 1 or 2 nitrogen atoms,

n denotes 0 or 1,

m denotes 1 or 2,

15 R^5 denotes a group selected from among optionally substituted morpholinyl,
piperidinyl, piperazinyl, piperazinylcarbonyl, pyrrolidinyl, tropenyl, R⁸-
diketomethylpiperazinyl, sulphoxomorpholinyl, sulphonylmorpholinyl,
thiomorpholinyl, -NR⁸R⁹ and azacycloheptyl,

R^6 , R^7 which may be identical or different, denote hydrogen or C₁-C₄-alkyl,
20 and

R⁸, R⁹ denote unsubstituted nitrogen substituents at R⁵, which may be identical or
different, denote either hydrogen or a group selected from among C₁-C₆-alkyl, -C₁-C₄-
alkyl-C₃-C₁₀-cycloalkyl, C₃-C₁₀-cycloalkyl, C₆-C₁₄-aryl, -C₁-C₄-alkyl-C₆-C₁₄-aryl,
pyranyl, pyridinyl, pyrimidinyl, C₁-C₄-alkyloxycarbonyl, C₆-C₁₄-arylcarbonyl, C₁-C₄-
25 alkylcarbonyl, C₆-C₁₄-arylmethyloxycarbonyl, C₆-C₁₄-arylsulphonyl, C₁-C₄-
alkylsulphonyl and C₆-C₁₄-aryl-C₁-C₄-alkylsulphonyl,

optionally in form of its tautomers, racemates, enantiomers, diastereomers and the
mixtures thereof and optionally in form of the pharmacologically acceptable acid
addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives
30 or prodrugs thereof,

for the preparation of a pharmaceutical composition for the treatment of diseases
characterized by abnormal cell proliferation in a human or non-human mammalian
body by inhibition of polo like kinases as mitotic regulators.

2. Use of a compound of general Formula (I) according to claim 1, wherein

5 R^1 to R^4 , R^6 and R^7 are as hereinbefore defined, and

L denotes a linker selected from among optionally substituted C_2 - C_{10} -alkyl, C_2 - C_{10} -alkenyl, C_6 - C_{14} -aryl, $-C_2$ - C_4 -alkyl- C_6 - C_{14} -aryl, $-C_6$ - C_{14} -aryl- C_1 - C_4 -alkyl, optionally bridged C_3 - C_{12} -cycloalkyl and heteroaryl which contains 1 or 2 nitrogen atoms

n denotes 1

10 m denotes 1 or 2

R^5 denotes a group which is bound to L via a nitrogen atom, selected from among optionally substituted morpholinyl, piperidinyl, R^8 -piperazinyl, pyrrolidinyl, tropenyl, R^8 -diketomethylpiperazinyl, sulphoxomorpholinyl, sulphonylmorpholinyl, thiomorpholinyl, $-NR^8R^9$ and azacycloheptyl,

15 R^8 , R^9 denote unsubstituted nitrogen substituents at R^5 , which may be identical or different, hydrogen or a group selected from among C_1 - C_6 -alkyl, $-C_1$ - C_4 -alkyl- C_3 - C_{10} -cycloalkyl, C_3 - C_{10} -cycloalkyl, C_6 - C_{14} -aryl, $-C_1$ - C_4 -alkyl- C_6 - C_{14} -aryl, pyranyl, pyridinyl, pyrimidinyl, C_1 - C_4 -alkyloxycarbonyl, C_6 - C_{14} -arylcarbonyl, C_1 - C_4 -alkylcarbonyl, C_6 - C_{14} -arylmethyloxycarbonyl, C_6 - C_{14} -arylsulphonyl, C_1 - C_4 -alkylsulphonyl and C_6 - C_{14} -aryl- C_1 - C_4 -alkylsulphonyl.

3. Use of a compound of general Formula (I) according to claim 1 or 2, wherein

R^1 to R^4 , R^6 and R^7 are as hereinbefore defined,

25 L denotes a linker selected from among optionally substituted C_2 - C_{10} -alkyl, C_2 - C_{10} -alkenyl, C_6 - C_{14} -aryl, $-C_2$ - C_4 -alkyl- C_6 - C_{14} -aryl, $-C_6$ - C_{14} -aryl- C_1 - C_4 -alkyl, optionally bridged C_3 - C_{12} -cycloalkyl and heteroaryl which contains 1 or 2 nitrogen atoms










n denotes 0 or 1





























m denotes 1 or 2







30 R^5 denotes a group which is bound to L via a carbon atom, selected from among R^8 -piperidinyl, R^8R^9 -piperazinyl, R^8 -pyrrolidinyl, R^8 -piperazinylcarbonyl, R^8 -tropenyl, R^8 -morpholinyl and R^8 -azacycloheptyl,
and

R^8 , R^9 denote unsubstituted nitrogen substituents at R^5 , which may be identical or different, hydrogen or a group selected from among C_1 - C_6 -alkyl, $-C_1$ - C_4 -alkyl- C_3 - C_{10} -cycloalkyl, C_3 - C_{10} -cycloalkyl, C_6 - C_{14} -aryl, $-C_1$ - C_4 -alkyl- C_6 - C_{14} -aryl, pyranyl, pyridinyl, pyrimidinyl, C_1 - C_4 -alkyloxycarbonyl, C_6 - C_{14} -arylcarbonyl, C_1 - C_4 -alkylcarbonyl, C_6 -
 5 C_{14} -arylmethyloxycarbonyl, C_6 - C_{14} -arylsulphonyl, C_1 - C_4 -alkylsulphonyl and C_6 - C_{14} -aryl- C_1 - C_4 -alkylsulphonyl.

4. Use of a compound of general Formula (I) according to claim 1, wherein the compound is selected from the group consisting of the compounds of Formula (I) shown
 10 in the following Table

						
Example	R^1	R^2	Config. R^1 or R^2	R^3	R^4	$L_n-R^5_m$
27	H		R			
44	H		R		H	
55	H		R			

58	H		R			
102	H		R			
103	H		R			
105	H		R			
110	H		R			
115	H		R			
133	H		R			
134	H		R			

234	H		R			
240	H		R			

wherein the abbreviations X_1 , X_2 , X_3 , X_4 and X_5 used in the Table in each case denote a link to a position in the general Formula shown in the Table instead of the corresponding groups R^1 , R^2 , R^3 , R^4 and $L-R^5$.

5

5. Use according to any one of claims 1 to 4, characterized in that the polo-like kinase is PLK-1.

6. Use according to any one of claims 1 to 4, characterized in that the disease is characterized by inappropriate cellular proliferation, migration, apoptosis or angiogenesis.

7. Use according to any of the preceding claims, characterized in that the disease is cancer selected from the group consisting of carcinomas, sarcomas, melanomas, myeloma, hematologic neoplasias, lymphomas and childhood cancers.

8. Use according to claim 7, characterized in that the cancer is leukaemia.

9. Use according any one of claims 1 to 8, characterized in that the disease is cancer selected from the group consisting of mixed tumors, undifferentiated tumors and metastases thereof.

10. Use of a compound according to any one of claims 1 to 4, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates,

hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of autoimmune disorders selected from the group consisting of Amyloidosis, Systemic lupus erythematosus, Rheumatoid Arthritis, Crohn's disease, multiple sclerosis, systemic sclerosis
5 (scleroderma), mixed connective tissue disease, Sjögren's syndrome, ankylosing spondylitis, autoimmune vasculitis, Behcet's syndrome, psoriasis, autoimmune arthritis, sarcoidosis and diabetes mellitus.

11. Use of a compound according to any one of claims 1 to 4, optionally in form of
10 its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the local or systemic treatment of fungous diseases.

15

12. Use according to claim 11, characterized in that the disease is selected from the group consisting of candidiasis, cryptococcosis, aspergillosis, mucormycosis, tinea, dermatophytosis, histoplasmosis, blastomycosis, coccidiosis and pneumocystis.

20 13. Use according to any one of the preceding claims, wherein the active ingredient is administered orally, enterically, transdermally, intravenously, peritoneally or by injection.

14. Method for treating a disease characterized by abnormal cell proliferation in a
25 human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators comprising administering to the mammal a therapeutically effective amount of a compound according to any one of claims 1 to 4, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates,
30 hydrates, polymorphs or physiologically functional derivatives thereof.

15. Method for treating patients who suffer from one or more diseases cited in any one of claims 6 to 12, comprising administering to the patient a therapeutically effective

amount of a compound according to any one of claims 1 to 4, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs or physiologically functional derivatives thereof.

